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Transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic 
valve replacement (TAVR), is a new technique for treating severe, symptomatic aortic 
stenosis. The mean age for TAVI patients is over 80 years and most of the patients 
have comorbidities and frailty. Some patients may be too frail and have a short life 
expectancy even after the intervention, and will benefit more from a palliative 
approach. Established surgical scores have limitations in determining risk among 
candidates for TAVI. Assessment of frailty might help to estimate the mortality risk 
and identify patients likely to benefit from treatment. On the other hand, there is a risk 
of ageism and undertreating older adults. How can we select the right patients for the 
procedure? Patient autonomy is a leading principle in bioethics and a basis for shared 
decision-making. In the light of the increasing focus on patient-centred care, this 
project has explored TAVI patients’ experience of the decision-making process 
preceding intervention. This thesis consists of three studies focusing on the decision-
making process prior to TAVI. Paper 1 focuses on the patient perspective, paper 2 
takes the doctors’ viewpoint and paper 3 includes both perspectives. 
 
Aims 
The aim of paper one was to explore conditions for autonomous choice as experienced 
by older adults who recently underwent transcatheter aortic valve implantation.  
 
The aim of paper two was to develop a frailty score to guide the decision for TAVI. 
 
The aim of paper three was to examine baseline characteristics and clinical outcomes 
important to older adults and their doctors to enhance shared decision-making prior to 




Materials and methods 
We conducted a mixed method study, with one qualitative sub-study (paper 1) and two 
quantitative sub-studies (papers 2 and 3).  All patients underwent TAVI due to severe 
and symptomatic aortic stenosis. The qualitative study involved semi-structured 
interviews of a purposive sample of ten older adults after the procedure. Analysis was 
by systematic text condensation. 
In paper 2 we conducted a prospective observational study in 82 patients ≥70 years 
accepted for TAVI from 2013 to 2015 and 65 patients ≥ 80 years (from a concomitant 
study on delirium) accepted from 2011 to 2013, giving a total of 147 patients. Prior to 
the procedure, a geriatric assessment (GA) was completed in 142 patients (missing 
data for calculating frailty score in five patients). Based on this, an eight-element 
frailty score with a 0–9 (least frail to most frail) scale was developed. In paper 3 we 
conducted a prospective, observational study of 82 TAVI patients ≥70 years (the last 
cohort of study 2), with two-year follow-up focusing on baseline frailty status 
(including cognitive deficits) and outcome measures important for shared decision-
making prior to the procedure.  
 
Results 
In paper 1, the median age of the included patients was 83.5 years (range 73-89 years). 
Even when choice seemed difficult or lacking, TAVI patients deliberately took the 
chance presented to them by taking into account risk assessment, ambivalence and 
fate. They regarded declining the treatment as worse than accepting the risk related to 
the procedure. The experience of being carefully advised by their doctor formed the 
basis of autonomous trust. This trust mitigated ambivalence about the procedure and 
risks. TAVI patients claimed that it had to be their decision and expressed feelings 
consistent with self-empowerment. Despite this, choosing the procedure as an 
obligation to their family or passively accepting it were also reported.  
In paper 2, patients had a mean age of 83 (SD 4) years, and 54% were women. The 
novel GA frailty score predicted two-year mortality in Cox analysis, also when 
adjusted for gender, age and logistic EuroSCORE (HR 1.75, 95% CI: 1.28–2.42, P < 
0.001). A ROC curve analysis indicated that a GA frailty cut-off score of ≥ 4 predicted 
xii 
 
two-year mortality with a specificity of 80% (95% CI: 73%–86%) and a sensitivity of 
60% (95% CI: 36%–80%), and the area under the curve was 0.81 (CI 0.71–0.90). All-
cause two-year mortality was 11%. 
In paper 3, mean age was 83 years (SD 4.7) and 48% were women. Fifteen patients 
(18%) had a Mini Mental Status Examination (MMSE) score below 24 points at 
baseline, indicating cognitive impairment or dementia, while five patients had an 
MMSE below 20 points. At baseline and six months, mean New York Heart 
Association (NYHA) class was 2.5 (SD 0.6) and 1.4 (SD 0.6) (p<0.001) respectively. 
Between baseline and six months there was no change in the mean scores on the 
Nottingham Extended Activities of Daily Living (NEADL) scale, with 54.2 (SD 11.5) 
and 54.5 (SD 10.3) points, mean difference 0.3 (p =0.7). At two years, six patients 
(7%) had died, four (5%, n=79) lived in a nursing home, six (7%) had contracted 
infective endocarditis, and four (5%) had had a disabling stroke.  
 
Conclusion  
This study provides empirically-based descriptions of the conditions for TAVI 
patients’ autonomy as experienced in the decision-making process, to assist clinicians 
obtaining valid informed consent. We found that a frailty scale based on geriatric 
assessment predicted two-year mortality in TAVI patients beyond the established risk 
score. Patients had symptom improvement and could maintain activities of daily living 
six months after TAVI, and had low mortality after two years. Rarely, severe 
complications occurred, such as stroke and endocarditis. Some patients had cognitive 
impairment or dementia at baseline, which might have influenced the decision-making 
process. Our findings provide support to identify patients with higher risk and lower 
expected benefit after TAVI, and circumstances under which the procedure might be 
futile. The decision to offer the procedure should be a careful evaluation by the heart 
team, and involve considering frailty, symptom burden and technical challenges, and 
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Due to the demography of an ageing population, decision-making in the oldest patients 
is increasingly important. Severe and symptomatic aortic stenosis has a high mortality 
rate without a new valve implantation. With advancing age, frailty and comorbidity, 
life expectancy might be short even after TAVI, and some patients may benefit from a 
palliative approach. The European Society of Cardiology (ESC) recommends an 
objective assessment of frailty before treatment decisions in patients with severe, 
symptomatic aortic stenosis; however, it has not been established which frailty 
assessments and which cut-offs should be used. Little is known about TAVI patients’ 
motivation for the procedure and their experiences of autonomy in the preceding 
decision-making process. Shared decision-making is recommended to address these 
issues but can be difficult to achieve, and there may be limitations to the concept in 
certain circumstances.  
 
1.1 Aortic stenosis and treatment options 
1.1.1 Aortic stenosis (AS) 
Degenerative calcific aortic stenosis is a common valve disease, with increasing 
prevalence due to the ageing population [1]. The prevalence of AS increases from 4% 
in 70- to 79-year-olds to 10% in the 80-89 age group [2]. Classification of the severity 
of AS is based on echocardiography; high gradient aortic stenosis with a valve area < 1 
cm2 and mean gradient > 40 mmHg, low-flow, low-gradient aortic stenosis with 
reduced or preserved ejection fraction and normal-flow, low-gradient aortic stenosis 
with preserved ejection fraction. Details of this assessment will be found in the ESC 
guideline documents [1]. When patients with severe AS develop typical symptoms like 
syncope, angina or dyspnoea, the prognosis is poor without intervention [1], usually 
stated as a two-year survival rate of 50% [3, 4].  
 
1.1.2 Surgical aortic valve replacement 
Surgical aortic valve replacement (SAVR) has been a treatment option for AS since 
the 1960s. However, about 30% of the patients were denied surgery due to high risk, 
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and most were older adults [5]. Multivariate risk scores evaluating both cardiac and 
extra-cardiac factors are used to define high-risk patients, such as the Society of 
Thoracic Surgeons score [6] and the EuroSCORE [7]. SAVR involves splitting of the 
sternum, a general anaesthetic, a heart-lung machine, an operating time of 3-5 hours, a 
hospital stay of 5-10 days and 2-3 months recovery time [8].  
 
1.1.2 Transcatheter aortic valve implantation  
Since it was first performed in 2002 [9], TAVI has emerged as an option for 
inoperable or high-risk patients with severe, symptomatic aortic stenosis. TAVI is non-
inferior or superior to SAVR in high-risk patients [10], and superior to standard care 
(which often included balloon aortic valvuloplasty) in inoperable patients [3]. Later 
studies have proven TAVI superior to SAVR when femoral TAVI access is used in 
intermediate-risk patients. For low-risk and younger patients, recent studies 
demonstrated comparable safety and efficiency of TAVI and SAVR, with one-year all-
cause mortality, short-term and one-year stroke and myocardial infarction similar in 
both groups [11]. At present, transcatheter aortic valve implantation is not 
recommended in asymptomatic patients by the European valve guidelines [1]. The 
concept of frailty, as defined below, has been related to TAVI from the beginning, as 
TAVI was initially developed for patients with severe aortic stenosis considered too 
frail for surgery [12]. The ESC states: “criteria for when TAVI should no longer be 
performed since it would be futile need to be further defined” [1]. The procedure takes 
under two hours, hospital stay is usually 2-5 days and recovery time is about one 





Figure 1: Illustration of the TAVI procedure: “The transcatheter valve is placed at the level of the native 
aortic valve during the final step of valve replacement, when the balloon is inflated within the native 
valve during a short period of rapid ventricular pacing. The delivery system is shown when it has 
traversed the aorta retrograde over a guidewire from its point of insertion in the femoral artery 
(transfemoral placement). Before balloon inflation, the valve and balloon are collapsed on the catheter 
(dark blue) and fit inside the sheath (blue). After balloon inflation, the calcified native valve (upper 
panel) is replaced by the expanded transcatheter valve (lower panel, shown in short-axis view from the 
aortic side of the valve)”. Reproduced with permission from [10]. Copyright Massachusetts Medical 
Society. 
 
1.1.3 Conservative strategy and transition to palliative care 
The ESC guideline on valvular heart disease has limited recommendations on how to 
provide care for patients refused for both surgery and TAVI [1]. Most patients with 
severe aortic stenosis progress to heart failure before death [13], and recommendations 
for palliative care in heart failure [14] are emphasized to guide clinicians [13]. 
Palliative care is an approach that improves quality of life for patients with life-
limiting conditions and their families, by early identification and treatment of 
symptoms and other physical, psychosocial and spiritual problems [15]. Some centres 
have developed palliative care services for patients when TAVI is regarded as futile 
[13]. However, only a small percentage of heart failure patients are referred to 
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palliative care [16]. Further research on how to provide palliative care to patients with 
heart failure is warranted. Traditionally cardiologists have reported an unwillingness to 
discuss information such as poor prognosis [17]. In a recent expert position statement 
for people living with heart failure, the authors highlight that palliative care improves 
quality of life and should complement cardiac care, instead of being seen as an 
alternative to it [18].  
 
1.2 The decision-making process 
1.2.1 The heart team 
It is recommended that all decisions on treatment for severe, symptomatic aortic 
stenosis are discussed in a heart team with particular expertise in valvular heart disease 
(VHD). The team should consist of “cardiologists, cardiac surgeons, imaging 
specialists, anaesthetists and, if needed, general practitioners, geriatricians and heart 
failure, electrophysiology or intensive care specialists” [1]. 
 










The ESC recommends a heart team to evaluate the severity and the aetiology of the 
VHD, the symptom burden and the likelihood that the symptoms are caused by VHD. 
They also recommended assessing life expectancy, expected quality of life, benefit-
risk assumption, optimal treatment modality and patient preferences [1]. Where life 
expectancy is below one year, it is not recommended to perform TAVI, yet no 
standard means of prognostication is suggested. 
In 2017, the American College of Cardiology (ACC) published an expert consensus 
pathway for TAVI in aortic stenosis patients [20]. This document discusses in detail 
the possibility of TAVI being futile and recommends methods to assess frailty, an 
aspect that is scarcely mentioned in the European Valve Guidelines. The ESC 
guidelines state that age ≥ 75 years, presence of severe comorbidity and frailty favour 
TAVI over SAVR [1]. However, there is also an understanding that for the frailest 
patients TAVI might be futile and a conservative approach is recommended for these 
patients [21]. 
 
1.2.2 Established risk scores 
Operative mortality is estimated by different multivariate scoring systems based on 
combinations of risk factors. The two most common are the European System for 
Cardiac Operative Risk Evaluation (EuroSCORE), [7, 22] and the Society of Thoracic 
Surgeons score (STS score) [6]. These successfully distinguish between high-risk and 
low-risk patients, but lack accuracy in estimating operative mortality in individual 
patients, and have major limitations in not including risk factors such as frailty [23]. At 
present there is no established TAVI risk score; however, when deciding between 
SAVR and TAVI, the ESC guidelines state that STS≥ 4% and logistic EuroSCORE ≥ 
10% favour TAVI [1]. 
 
1.2.3 Autonomy and shared decision-making  
Previously, paternalism was the common basis for decision-making in medicine, 
where doctors made treatment decisions without involving the patient. The aims of 
medicine were defined in objective terms, such as “maximizing health or prolonging 
life” [24]. Even though paternalism still exists in medicine and may be the preferred 
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model for instance in emergency care in which shared decision-making has limitations, 
the latter is now the ideal. This involves the patient in treatment decisions and 
recognizes that “the patient`s well-being should be the essential aim of medicine, and 
it has a substantial ‘subjective’ component”, due to the patient’s goals and values [24]. 
However, treatment decisions for older adults may entail both paternalist and 
autonomous factors [25]. Autonomy is a core element of shared decision-making and 
forms the basis of informed consent. Autonomy is defined by Beauchamp and 
Childress as based on three conditions, intentionality, understanding and non-control 
[26]. Autonomy does not mean, however, that patients freely can choose their 
treatment. “The authority of the patient to order a particular treatment, however, is 
more limited than the authority to refuse one” [24]. This will also depend on the health 
care setting and priorities in the patient`s location.  
In Norway, health care is mostly publicly funded, and national priorities will impact 
patients’ possibilities to choose treatment [27].  Patients are not free to choose between 
SAVR and TAVI or between TAVI and conservative treatment. Treatment decisions 
are made in the heart teams at university hospitals, preferably supplemented by doctors 
who know the patients. The legislation stipulates that patients should be involved in 
decision-making [28] and the Minister of Health also highlighted this in his speech to 
the specialist health care services in 2018, with the words: “No decision about me, 
without me” (first stated by the UK Secretary of State for Health, Andrew Lansley, in 
2010 [29]) and the Minister also stated that patient involvement must be the rule in all 
health care services [28]. However, the extent to which this is implemented is 
unknown and difficult to measure. We therefore wished to investigate how older adults 
undergoing TAVI experience conditions for autonomous decisions. 
 
1.2.4 Cognitive impairment and informed consent 
The population of older adults is growing and the number of patients with cognitive 
impairment and dementia increases with higher age [30]. Health care workers need to 
be aware that some older patients have reduced capacity to give an informed consent 
to treatment and to participate in shared decision-making [31]. To provide an informed 
consent the patient needs to communicate a choice, understand the information, be 
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aware of the situation and its consequences and reason about treatment options [32]. In 
Norway, when patients lack capacity to participate in decision-making, health care 
may be provided if it is likely  that the patient would have consented to and preferred 
treatment. If possible, the patient’s family should be contacted to provide information 
of what the patient would have wanted [28]. This thesis also explores the challenges of 
decision-making regarding TAVI in the context of cognitive impairment in order to 
assist both clinicians and patients in making the optimal choice. 
 
1.2.5 Futility 
Therapeutic futility is defined as lack of medical efficiency, particularly when the 
therapy is unlikely to produce its intended clinical result, as assessed by the doctor, or 
lack of a meaningful survival, as considered in relation to the personal values of the 
patient [33]. It is well-documented that TAVI improves symptoms and prolongs life, 
and most older adults with severe symptomatic AS would benefit from valve 
implantation. In some patients, however, judging benefit versus futility in TAVI 
patients is complex and must integrate different information to facilitate a shared 
decision [34].  
 
1.3 Frailty 
1.3.1 Definition of frailty 
Frailty is defined as a state of reduced physiological reserve and diminished resistance 
to stressors, which increases the risk of adverse outcome [35, 36]. Stressors are 
classified as acute or chronic disease or iatrogenic, such as surgery or intervention 
[12]. The prevalence of frailty increases with age and it is more common in women 
[37]. Most older adults over 85 years are not frail, demonstrating the concept of 
biological versus chronological age [38] and the considerable variation among the 
oldest patients. However, there is no consensus on the definition. Several attempts 
have been made to reach agreement, but have been unsuccessful due to the inability to 
settle for a “single operational definition of frailty that can satisfy all experts” [39]. 
Physical frailty based on the Fried criteria [35] or the frailty index of Rockwood [40], 
based on an accumulation of deficits, are the two most widespread approaches to 
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frailty. The physical phenotype of frailty shows significant overlap with sarcopenia 
[41], which is defined as a progressive and generalized muscle disorder. Severe 
sarcopenia is characterized by low muscle strength, low muscle quantity/quality and 
low physical performance [42]. Evaluating sarcopenia by measuring psoas muscle area 
and volume with a validated CT method outperformed other frailty assessments in 
predicting long-term mortality in TAVI patients [43]. 
Further, a method based on comprehensive geriatric assessment (CGA), without 
adopting the strict criteria of the frailty index, has also been used [44, 45].  The 
concept of frailty is used for different purposes, including identification of older adults 
in the community to prevent or delay functional decline and to decide which 
intervention should be implemented at specific time points [46]. In order to inform 
treatment strategy, the concept of physical frailty is insufficient; assessment of 
cognition and psychological status is also needed. Frailty defined on the basis of CGA 
is more applicable in clinical practice and therefore used in this thesis, inspired by the 
work of Kristjansson et al. and Stortecky et al. [45, 47]. The impact of heterogeneity in 
older age has been a focus of increasing interest in research, illustrated by the 
escalation in the number of PubMed papers on “frailty” from 74 in 2001 to 1988 in 
2018. Even when procedures have low risk, frail patients still have higher risk of 
adverse outcomes [48].  
 
1.3.2. Comprehensive geriatric assessment and geriatric assessment 
Older adults might have complex, multiple and overlapping problems. Specialist co-
ordinated care was developed to categorize the different components contributing to 
loss of function and disease. Comprehensive geriatric assessment (CGA) is a 
systematic examination of independence, physical functioning, comorbidity, 
polypharmacy, cognition, nutritional state, social network and emotional state in older 
adults [49]. A variety of different tests are used in a multidisciplinary team, assessing 
the different domains in order to tailor treatment to patient needs. We chose to use the 
term geriatric assessment (GA) for the frailty score used in this thesis because this has 
been used in similar publications focusing on preoperative assessment to identify 
frailty [50].   
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1.3.3 Predictive value of frailty assessment before TAVI  
In the first paper on frailty screening before TAVI, a frailty index was constructed 
based on multidimensional geriatric assessment, including independence, cognition, 
nutrition and mobility. The authors demonstrated that this construct added information 
to the already existing  risk scores in predicting mortality and morbidity [47]. 
Subsequently, several frailty scores have been advocated, both single-item screening 
followed by a more thorough examination, and more multifaceted assessments [12, 
51]. Guidelines recommend measures of frailty, not subjective “eyeballing” or “end of 
the bed” assessments, to increase objectivity [1, 38]. In a systematic review on 
preoperative frailty and outcomes after TAVI from 2017, including 10 studies from 
Europe and North America and 4592 patients, the authors found that although the 
frailty instruments varied, measurement of frailty identified a population at double risk 
of both early (≤ 30 days) and late (>30 days) mortality [38]. 
Afilalo et al. [52] compared the incremental prognostic value of seven different frailty 
scores to predict poor outcomes following TAVR or SAVR and found that a brief 4-
item scale encompassing lower-extremity weakness, cognitive impairment, anaemia 
and hypoalbuminemia outperformed other frailty scores. Despite a growing body of 
publications, there still is a need for research addressing the clinical applicability and 







The overall aim of this thesis was to provide support in treatment strategies for frail 
older adults with severe aortic stenosis, where the TAVI procedure might be futile. We 
defined the following objectives to achieve this goal: 
  
1. To explore conditions for autonomous choice as experienced by older adults who 
recently underwent trans-catheter aortic valve implantation.  
 
2. To develop a frailty score to guide the decision for TAVI.  
 
3. To examine baseline characteristics and clinical outcomes important to older adults 







3.1 Study setting (all three papers) 
All studies were performed in different subsamples of 147 patients admitted to 
Haukeland University Hospital to undergo TAVI. Eighty-two patients ≥70 years were 
included from October 2013 to April 2015 (studies 2 and 3). Of these 82 patients, 12 
were included in the qualitative study (study 1). Another 65 patients ≥ 80 years were 
also participating in a concomitant study of delirium, between February 2011 to 
September 2013 (study 2) [53]. Haukeland University Hospital provides all SAVR and 
TAVI in Western Norway (serving a population of 1.1 million). The TAVI programme 
at this hospital started in 2010, with an increase in the number of procedures every 
year since then, reaching 126 TAVI procedures performed in 2018 [54].  
The hospital has advanced interventional and surgical expertise. All patients in the 
study were discussed by a heart team including (as a minimum) cardiac surgeons, 
interventional cardiologists and imaging specialists, and often a doctor from the ward 
familiar with the patient, before TAVI treatment was offered.  
 
3.2 Ethical considerations 
Older adults are underrepresented in clinical research and considered more vulnerable 
and complex, making research challenging. In order to provide treatment with 
beneficence, non-maleficence and justice, we regard it as important also in an ethical 
perspective to perform studies in this age group. The studies in this thesis follow the 
principles of the Declaration of Helsinki, and were approved by the Regional 
Committee for Medical Research Ethics (REK 2010/2936-6 and 2013/1310). The 
studies included the usual care and no interventions; however, questionnaires and 
testing of cognition, emotional status and physical frailty (by LPE/ES at baseline) 
might have distressed patients and we strove to provide a calm and comfortable 
environment, reassuring the patients after testing. The numbers of questions and tests 
were kept at a minimum. For the qualitative interviews, patients seemed pleased to be 
visited and interviewed, expressing that they wanted to contribute to research and 
appreciated that their voice was being heard. Data were entered into a secure research 
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database at the hospital, and only a few members of the research team had access. All 
paper versions of questionnaires and tests were numbered and stored separately from 
personally identifying data. Patient identification linked to numbers was locked away 
in a separate cabinet where only ES had access.  
Papers 2 and 3 have multiple co-authors to ensure interdisciplinary perspectives 
crucial to TAVI treatment, thus enhancing the likelihood of developing knowledge of 
clinical relevance and impact. None of the authors reported any conflict of interest, 
and none of the funders have influenced the thesis or papers in any way. 
 
3.3 Study design and analysis, study 1 
A qualitative design is recommended to investigate human experiences, motivation, 
interaction and thoughts, developing new knowledge that cannot be generated using 
quantitative methods [55, 56].  
The qualitative study was conducted according to Kvale’s principles for semi-
structured individual interviews. These principles guided the interviews in terms of 
thematizing, designing, the interview situation, how to perform transcription, analysis, 
interpretation, verification and reporting of the results [57] .  
 
3.3.1 Data collection 
Patients over 70 years were eligible for the study and were included before discharge 
from hospital, but after TAVI. We sought a purposive sample, emphasizing diversity 
in age, gender and complication rate. The only exclusion criteria was lack of fluency in 
Norwegian. Participants were approached face to face by the principal investigator on 
the ward, and all signed an informed consent.  
The first interview was performed on 9 February 2014 and the last on 24 April 2015. 
All interviews were conducted by the same researcher 9 to 52 days after TAVI, most 
of them two to four weeks post-procedure. Two of the interviews (interviews 3 and 4) 
were conducted late after TAVI because the analysis process took more time than 
expected (patients were included during index hospital stay) and revision of the 
interview guide. Even though this delay might have caused recall bias, the patients 
involved were cognitively well-functioning and did not have any difficulty in recalling 
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the decision-making process. Interviews lasted from 30 minutes to one hour, and were 
terminated when all aspects of the interview guide had been covered. A semi-
structured interview implies that the researcher does not rigorously follow the 
interview guide, but allows the conversation to develop around the main theme of the 
study. No interviews were ended due to interruption. One patient was interviewed at 
the local hospital, two in a rehabilitation facility and the remainder in the patient’s 
home. In one interview the patient’s spouse was in the same room but did not 
participate in the interview. In the other interviews only the researcher and patient 
were present. All interviews were audiotaped and transcribed verbatim by the primary 
investigator and analysed manually (without software). We gave the patients fictitious 
names from the outset. Field notes were taken before and after the interviews.  
Thirteen patients were invited, twelve were included, one withdrew and one was 
unable to attend the interview. Ten patients were therefore interviewed. The interviews 
were conducted using an interview guide, see the Appendix. The questions in the 
interview guide were developed through discussions between MAS and ES (see list of 
authors in paper 1). The questions explored why the patients wanted TAVI, how they 
experienced the information they received, difficulties in decision-making, risk of 
death, how they involved their family members, what hopes for the future were 
important to them and how they felt taken care of by health care professionals during 
the process. After the first two interviews, the guide was revised to add “What were 
your expectations?”, “How much detail would you prefer in the information about risk 
before this intervention?” and “Could you tell me a bit about how you typically face 
challenges/hard times in life?” These questions were added in order to further explore 
motivation, communication preferences and coping strategies. Based on consecutive, 
stepwise analysis of the interviews, the aims of the study were readjusted to focus 
specifically on clinical ethics and experienced conditions for autonomous choice 
preceding TAVI, after initially mapping general patient perspectives and experiences 





Ten patients were interviewed with an age span from 73 to 89 years, median age 83.5 
years. Five lived alone and five lived with their spouse. Three scored 10 or more 
points on the Short Physical Performance Battery (SPPB), six scored between 7 and 9, 
and one had a score below 6 points, indicating physical frailty. The SPPB is a 
validated test for lower extremity function, including balance, walking speed and chair 
stand. It has a range from 0 to 12, where a higher score indicates better function [58]. 
Six had a Mini Mental Status Examination (MMSE) score [59] over 27 at baseline, 
while four had MMSE 25-27. The EuroSCORE [7] was 10-20 in seven patients, two 
had a score below 10, and one over 20. Three received a pacemaker and two had 
severe complications post-procedure. In this early TAVI era, the length of stay (LOS) 
was significantly longer than today. In 2018 median LOS after TAVI was three days at 
Haukeland University Hospital [54], while in the present study six patients stayed 6-7 
days, one five days, one 10, one 11 and one 17 days. Five were discharged to home, 
one to the local hospital, three to rehabilitation and one to intermediate care in a 
nursing home. Eight were Christians, one was a member of the Norwegian Humanist 
Association, and one did not have a clearly defined religious belief. Their previous 
work was very varied, e.g. housewife, factory worker, musician, professor, carpenter, 
home-care attendant, entrepreneur and insurance agent. 
 
3.3.3 Analysis by systematic text condensation 
Qualitative analysis was performed by MAS and ES, using systematic text 
condensation (STC), as described by Malterud [60]. This is a cross-case, thematic 
analysis and a suitable method for developing new descriptions and concepts. One 
advantage of STC is the detailed description of the procedure, making it applicable for 
researchers without comprehensive theoretical training. We chose this procedure 
instead of other qualitative methods such as grounded theory because we had a well-
defined research aim focusing on patients’ experiences, rather than a desire to develop 
new classifications and theory [55]. The purpose is not to present a full range of 
phenomena, but vital examples from people’s life-world experiences. A decision trail 
documented the choices made during the analytical process [61]. The analysis was 
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stepwise, with new interviews supplementing the previous ones, and de- and 
recontextualization of the audiotaped transcribed text. We chose an editing analysis 
style, described by Crabtree and Miller [62], where categories develop from the 
empirical data instead of being predefined. However, theory of shared decision-
making [63] and autonomy [64, 65] inspired the analysis, and the different categories 
reflected this theoretical framework. Systematic text condensation consists of four 
stages [60]. 
 
1) From chaos to themes, total impression 
The first step consists of reading the material to get a sense of the whole, looking for 
preliminary themes, bracketing previous preconceptions. We started by reading the 
first two interviews, identifying themes that gained our attention. ES found eight 
themes and MAS found four. After discussion and negotiation we agreed on four 
themes, medically necessary, mobilization of power, information dilemma and fear 
and death. The categories represented empirical findings and were not identified in 
advance.  
 
2) From themes to codes, identifying and sorting meaning units 
We searched for elements of the text (“meaning units”) that addressed the experience 
of the decision-making process. This is a systematic line by line evaluation. “Meaning 
unit” is defined as a text fragment focusing on phenomena being investigated, not 
limited to sentences or comments, but including all parts of the text addressing the 
phenomenon, here the experience of the decision-making process. Then we started 
coding, where we identified, categorized and sorted meaning units related to the 
themes. This is called decontextualization, since fragments of the text are collected to 
be read together with similar text elements. During coding the code groups are 
elaborated from the themes from the first step of the analysis. This is a dynamic 
process and code groups develop during the analysis. We did this manually, by cutting 





3) From code to meaning - condensation 
We sorted the material in each code group into subgroups and reduced the content of 
each subgroup to a condensate. This is an artificial quotation in which patients’ own 
words from the meaning units are used to create a summary of the findings. 
Specifically for STC, the condensate incorporates all text from the meaning units and 
prevents the researcher from favouring meaning units supporting her preconceptions. 
The purpose of the artificial quotation is to translate the content in the subgroups to a 
more generalized version, rooted in the data, being a working paper for the final 
summary. After the first five interviews, we discussed relevant theoretical aspects 
which would give the analysis more focus and depth. We then decided to shift the 
centre of our attention from general patient experiences to clinical ethics, using theory 
of autonomy and shared decision-making.  
 
4) Descriptions and concepts, synthesizing from condensation  
In the last step, all parts were put together and recontextualized. Synthesizing the 
content of the condensate, we elaborated descriptions and concepts, providing 
trustworthy stories that clarified the study question. Relevant quotations were selected 
for each theme, illustrating the results of descriptions and concepts reflecting the most 
important aspects of the experienced conditions for autonomous choice reported by the 
patients. The relevant themes revealed in step 1 were elaborated through the analytic 
process, by coding meaning units, condensation and recontextualization, resulting in 
the final categories: “Deliberately taking the chance”, “Autonomous trust in their 
doctors” and “Fundamental self-determination based on personal identity”.  
 
3.4 Study design and analysis (studies 2 and 3) 
3.4.1 Study period and data collection 
One hundred and forty-seven TAVI patients were included, 82 patients ≥70 years from 
October 2013 to April 2015 and 65 patients ≥ 80 years, enrolled from February 2011 
to September 2013 from a concomitant study on delirium [53]. Patients were included 
and baseline examinations were performed the day before the procedure.  
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3.4.2. Assessment tools 
Mini Mental Status Examination (MMSE) 
The Mini Mental Status Examination is widely used for screening of cognitive 
function, with a range from 0 to 30 points, higher scores indicating better cognition. It 
is a test of orientation, memory, attention, calculation, ability to name, to follow verbal 
and written commands, and to copy a polygon [59]. It should be interpreted with 
caution, and not be used as a diagnostic test of cognitive impairment or dementia. High 
age and low education might give a low score despite normal cognition, and the test 
might also be influenced by hearing loss, visual difficulties and physical illness [59]. 
MMSE was performed by LPE and ES at baseline (see author list in paper 2).  
 
Nottingham Extended Activities of Daily Living (NEADL) 
NEADL is a measure of independence in instrumental activities of daily living (I-
ADL), beyond the basic ADL [66]. It assess mobility and kitchen, domestic and leisure 
activities. Each item is rated on a four-point scale from 0 to 3, (0=unable, 3=able) with 
higher scores representing higher independence. The maximum score is 66. NEADL 
was examined using a questionnaire at baseline (studies 2 and 3), and by telephone 
interviews at six months by ES in study 3 [66]. 
 
Study of osteoporotic fracture index (SOF index)  
Physical frailty was assessed by the SOF index [67], consisting of three components: 
weight loss (using a modified version with patient reported weight loss, not measured 
as in the original index), incapacity to rise from a chair five times without using one’s 
arms, and reduced energy level by answering “no” to the question “Do you feel full of 
energy?”. Physical frailty is defined when two or more of these three components are 
present [67]. Chair stand was tested by LPE and ES (see author list in paper 2) and 
weight loss and energy were patient-reported (questionnaire). All measures were 






Hospital Anxiety and Depression Scale (HADS) 
HADS [68] is a screening for mood disorders. It encompasses fourteen statements 
describing the patient’s feelings and emotions, with seven items in each of the 
subscales anxiety and depression. Scoring ranges from 0 to 3 indicating probable 
absence, possible presence and probable presence of clinically meaningful degrees of 
the mood disorder. The response alternatives for each question have minor differences; 
however, a typical statement is: “I feel cheerful” with response options of “not at 
all=3”, “not often=2”, “sometimes=1” and “most of the time=0”. The maximum score 
is 42, with a higher score representing probable/possible mood disorder. The HADS 
questionnaire was administered at baseline.  
 
Charlson Comorbidity Index   
The Charlson Comorbidity Index [69] is a commonly used index for assessing 
comorbidity. We searched the electronic medical records for previous diseases and 
thus did not consider comorbidity based on what was reported at this admission alone. 
The index consists of nineteen diseases, assigning different weighing depending on the 
severity of the disease, for instance one point for myocardial infarction, congestive 
heart failure, peripheral vascular disease and dementia, two points for hemiplegia, 
moderate or severe renal disease, three points for severe liver disease and six points for 
metastatic solid tumour and AIDS.   
 
Nutrition 
We assessed nutrition in two ways, calculating body mass index (BMI) and using the 
weight question from SOF [67], asking whether the person’s weight had increased, 
decreased or been stable in the past year. In order to simplify the presentation, we only 
listed BMI under nutrition in the frailty score. In calculating BMI, weight was 
measured for all patients, height was measured in the first 65 patients and was patient-




New York Heart Association (NYHA) 
We assessed the degree of symptoms of cardiac disease by NYHA classification [70], 
where NYHA class I represents no limitation of physical activity. Ordinary physical 
activity does not cause undue palpitation, fatigue dyspnoea, or angina pain. Class II: 
Slight limitation of physical activity, comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnoea, or angina pain. Class III: Marked limitation of 
physical activity, comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnoea, or angina pain. Class IV: Unable to carry on any physical 
activity without discomfort, symptoms of heart failure at rest. If any physical activity 
is undertaken, discomfort increases. NYHA at baseline was collected from the medical 
record and by telephone interview (ES) at six months.  
 
European System for Cardiac Operative Risk Evaluation (EuroSCORE) 
The logistic EuroSCORE [7, 71] is a scoring system estimating early mortality in heart 
surgery on the basis of objective risk factors. However, it overestimates 30-day 
mortality and ignores important risk factors like frailty, porcelain aorta and chest 
radiation therapy [1]. Low surgical risk by logistic EuroSCORE is defined with a score 
of <10%, intermediate risk 10-20%, and high surgical risk is defined as >20%. From 
2012, it is recommended to replace this score with EuroSCORE II. However, when we 
planned the study it was still the preferred score in clinical practice, and we chose the 
logistic score for better comparison of our study with other TAVI studies [38, 72]. 
The logistic EuroSCORE covers age, gender (higher risk in females), chronic 
pulmonary disease, extracardiac arteriopathy (claudication, carotid occlusion or >50% 
stenosis, previous or planned intervention on the abdominal aorta, limb arteries or 
carotids), neurological dysfunction, previous cardiac surgery, creatinine > 200 µmol/L, 
active endocarditis, critical preoperative state, unstable angina, left ventricle function, 
recent myocardial infarction, pulmonary hypertension (systolic artery pressure >60 
mmHg), emergency, other than isolated coronary artery bypass grafting, surgery on 
thoracic aorta and post-infarct septal rupture, giving different weight to the different 
domains. Neurological dysfunction is specified as disease severely affecting 
ambulation or day to day functioning. 
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3.4.3 Developing a novel frailty scale 
To support the decision-making process we developed a frailty score based on geriatric 
assessment. Studies define frailty differently, but the specific aim of this study was to 
help identify frail patients, thus informing clinicians and patients as to whether TAVI 
might be futile. The concept of physical frailty (Fried model [35]) was considered too 
narrow, excluding important domains like cognitive function. The additional 
advantage of GA is that it closely resembles clinical work, using validated, well 
known assessment tools proven feasible in older adults. It is based on few parameters 
with a high degree of transparency regarding which domain is frail (cognition, 
nutrition, etc.), making it easier to understand and communicate to other members of 
the heart team. This is in contrast to the frailty index, where there are at least 30 
recommended assessments, providing a score from 0 to 1, with a lower score 
indicating more severe frailty [73, 74]. The frailty score was inspired by the thesis of 
Siri Rostoft Kristjansson from 2011[75] on surgery in patients with colorectal cancer, 
where frailty categorization based on comprehensive geriatric assessment predicted 
morbidity and mortality. When we planned the study, only one paper provided 
information on prediction of frailty in a TAVI population [47].  
 
The statistical strategy is described by Harrell [76], where clinicians assign severity 
points to each condition and add the points to give a total score. Possible variables in 
the score were determined by the variables in the concomitant study on delirium [77], 
and the principal investigator (ES) sent e-mails to the geriatricians and the supervisors 
containing the different variables and explaining the principles from Harrell and 
asking them to provide a suggestion, and send it by return without copies to the others. 
The variables included assessment of cognition, instrumental activity of daily living, 
nutrition, physical frailty, comorbidity and psychological health. ES also provided a 
suggestion before reading the e-mails from the others. Independently, three 
geriatricians (AWS, AHR and ES, see author list paper 2) and one cardiologist (JEN, 
see author list paper 2) ranked the clinical severity of signs within each potential 
important domain. The different suggestions were sent to the first author who 
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developed a combined frailty score based on the different proposals, and returned this 
to the others. The researchers then agreed on the final score (Appendix). 
 
Table 1: Geriatric assessment tools used in the novel frailty score and the 
corresponding scoring scheme 
Domain Cut-off Points 






Instrumental activity of living NEADL ≤43 1 
Nutrition BMI < 20,5 1 
Energy level (SOF) Low energy 1 
Weight loss (SOF)a Weight loss 1 
Limb strength(SOF) Chair stand (not able) 1 
Comorbidity Charlson Comorbidity Index ≥3 1 
Psychological factors HADS (total score) ≥ 15 1 
Total Maximum score 9 
The total score is calculated by adding the different domain scores. BMI, Body Mass Index; HADS, 
Hospital Anxiety and Depression Scale; MMSE, Mini Mental Status Examination; NEADL, Nottingham 
Extended Activities of Daily Living Scale; SOF, Study of Osteoporotic Fractures Index. a Modified from 
the original SOF, by self-reporting weight loss, not measured.   
 
3.4.4 Statistics 
All statistical analyses in the papers were performed by an experienced biostatistician 
(KOH, see author list in papers 2 and 3).  We present the data as means and standard 
deviations, percentages and counts, or proportions and hazard ratios with 95% 
confidence intervals, as appropriate.  
 
Paper 2:  
To assess whether the new frailty score could predict mortality within two years, also 
when adjusted for other usual predictors, we fitted Cox regression models with Firth’s 
correction. Firth’s correction offers reduced bias when there are a small number of 
events (deaths) compared to the number of predictors. The regression models 
contained frailty score as a continuous predictor (unadjusted model and trend test), or 
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frailty score, gender, age and logistic EuroSCORE as predictors (adjusted model). We 
also fitted a similar adjusted model with frailty score as a dichotomized variable. Time 
to death stratified by frailty score (continuous or dichotomized) was demonstrated 
using Kaplan–Meier plots. Cut-off values for the dichotomized GA frailty score were 
found by examining the receiver operating characteristic (ROC) curve [78]. The area 
under the curve (AUC) was reported as a summary measure. We obtained two cut-off 
values with an estimated high sensitivity and specificity, and chose the one (≥ 4) that 
highlighted specificity over sensitivity. Confidence intervals for sensitivity and 
specificity were determined using the Wilson method [79]. 
We used IBM SPSS Statistics 24 and R version 3.5.0 for statistical analysis [80]. The 
ROC and AUC calculations were performed using the R ‘pROC’ package version 
[81], and the Cox regression with Firth’s correction was performed using the R 
‘coxphf’ package version 1.13 [82]. 
 
Paper 3: 
Changes from baseline to six months were analysed by paired t-tests. There were few 
missing data (< 6.1% for NEADL), and we therefore used complete case analysis and 
reported the number of observations each analysis was based on. We carried out 
statistical analysis in IBM SPSS Statistics 24 and R version 3.6.0 [80]. P-values <0.05 
were considered significant. 
 
3.4.5 Missing variables 
Some patients had missing data for a few of the questions in the HADS and NEADL 
questionnaires. Where there was no ambiguity as to which side of the cut-off the total 
frailty score would fall on, we used the data for these patients. Otherwise, the patients 
were excluded from analysis. We lacked data for calculating the frailty score in five 
individuals. In one secondary analysis based on the mEFT frailty scale, there were 
additional missing data from three patients. In paper 3 there were few missing data, 




4. Summary of results 
Paper 1 
Background and aims Patient autonomy is an important principle in bioethics and a 
basis for shared decision-making. This study explored conditions for autonomous 
choice as experienced by older adults who recently underwent TAVI.   
 
Methods and results This was a qualitative study involving semi-structured interviews 
of a purposive sample of ten older adults (range 73-89, median 83.5 years) after TAVI 
(median 23 days). The study setting was a department of heart disease at a university 
hospital performing TAVI since 2010. Analysis was by systematic text condensation.  
Even when choice seemed difficult or lacking, TAVI patients deliberately took the 
chance offered them by taking into account risk assessment, ambivalence and fate. 
They regarded declining the treatment as worse than accepting the risk related to the 
procedure. The experience of being carefully advised by their doctor formed the basis 
of autonomous trust. The trust they felt for the doctors’ recommendations mitigated 
ambivalence about the procedure and risks. TAVI patients expressed feelings 
consistent with self-empowerment and claimed that it had to be their decision. Despite 
this, choosing the intervention as an obligation to their family or passively accepting it 
were also reported.  
 
Conclusions Older TAVI patients’ experience of an autonomous decision may 
encompass a frank trade-off, deliberate dependency on the doctor as well as a resilient 
self-view. Doctors should be especially aware of how older adults’ cognitive ability 
subtly declines and how the inclination to preserve their identity can influence 
decision-making when obtaining informed consent. Cardiologists and other providers 






Background and aims: Established surgical scores have limitations in determining risk 
among candidates for transcatheter aortic valve implantation (TAVI). Assessment of 
frailty might help to estimate the mortality risk and identify patients likely to benefit 
from treatment. The aim of this study was to develop a frailty score to guide the 
decision for TAVI. 
 
Methods and results: We conducted a prospective observational study in patients ≥70 
years referred for TAVI during 2011-2015. A heart team had refused the patients for 
open heart surgery due to high risk but accepted them for TAVI. Prior to the 
procedure, a geriatric assessment (GA) was performed. Based on this, an eight-element 
frailty score with a 0-9 (least frail to most frail) scale was developed. A total of 142 
patients, 54% women, mean age 83 (SD 4) years, with severe and symptomatic aortic 
stenosis were assessed. All-cause two-year mortality was 11%. The novel GA frailty 
score predicted two-year mortality in Cox analysis, also when adjusted for age, gender 
and logistic EuroSCORE (HR 1.75, 95% CI: 1.28-2.42, p<0.001). A ROC curve 
analysis indicated that a GA frailty cut-off score of ≥4 predicted two-year mortality 
with a specificity of 80% (95% CI: 73%-86%) and a sensitivity of 60% (95% CI: 36%-
80%). The area under the curve was 0.81 (CI 0.71-0.90).  
 
Conclusion: A novel eight-element GA frailty score identified gradations of survival in 
patients refused for open heart surgery. Patients with higher GA frailty scores had 





Background and aims: Decision-making in frail older adults is challenging, where 
treating a single disease may have limited benefit due to other chronic conditions or 
functional decline. For older persons who are seriously ill, risk of losing independence 
might be more feared than death itself. The objective of this study was to examine 
baseline frailty status, including cognitive deficits and important clinical outcomes, to 
inform shared decision-making in older adults receiving Transcatheter Aortic valve 
Implantation (TAVI).  
 
Methods and results: We conducted a prospective, observational study of 82 TAVI 
patients, recruited from 2013 to 2015, with two-year follow-up. Mean age was 83 
years (SD 4.7). Eighteen percent of the patients were frail, as assessed with an eight-
item frailty scale. Fifteen patients (18%) had a Mini Mental Status Examination 
(MMSE) score below 24 points at baseline, indicating cognitive impairment or 
dementia, while five patients had an MMSE below 20 points. Mean New York Heart 
Association (NYHA) class at baseline and six months was 2.5 (SD 0.6) and 1.4 (SD 
0.6) (P<0.001). There was no change in the mean scores on the Nottingham Extended 
Activities of Daily Living (NEADL) scale between baseline and six months, at 54.2 
(SD 11.5) and 54.5 (SD 10.3) points respectively, mean difference 0.3 (p=0.7). At two 
years, six patients (7%) had died, four (5%, n=79) lived in a nursing home, four (5%) 
had had a disabling stroke and six (7%) had contracted infective endocarditis. 
 
Conclusion: TAVI patients had symptom improvement and could maintain activities 
of daily living at six months. They had low mortality and most patients lived in their 
own home two years after TAVI. Complications such as death, stroke and endocarditis 
occurred. Some patients had cognitive impairment before the procedure which might 
have influenced decision-making. Our findings may be used to develop pre-TAVI 






5.1 Methodological aspects (study 1) 
A qualitative design is suited to exploring patients’ perspectives, experiences or views 
in order to provide complex and detailed descriptions of a phenomena, generating new 
knowledge not possible to obtain from predefined questionnaires [55, 56]. Have we 
used the best methods to shed light on our research question? The qualitative research 
interview is a relevant method when we aim to explore the meaning of social 
phenomena as experienced by the people themselves, although there are limitations to 
this design [56]. 
 
5.1.1 Internal validity  
Contemporary qualitative studies belong to the tradition of postmodernism and social 
constructivism, in which the researcher is an active participant in the development of 
knowledge, and investigators are prepared to achieve partial understanding and to 
identify new questions about their research topic, rather than definite answers [56]. 
Internal validity asks whether the study investigates what it is meant to [55] or 
describes the phenomena that it was intended to describe, theorize or explain [62]. 
Among patients eligible for the study, we sought a sample with explicit variation, and 
the interviews contained rich and varied descriptions of the conditions for autonomy in 
the decision-making process [83]. Despite this, the questions in the interview guide 
might have been insufficient and different questions or another interviewer might have 
revealed other aspects [55]. Participants in studies differ in how personal they want to 
be, and some of the interviews were richer than others. During the interviews, patients 
disclosed both positive and negative aspects of the process they had been through, 
doctors they had seen and their own responses, suggesting that they answered honestly 
[57]. We aimed to achieve a quiet and calm atmosphere during the interviews, also 
when they were conducted in an institution [57]. The power asymmetry that normally 
exists in doctor-patient relationships may have been reduced by the interviewer not 
wearing a hospital uniform and being younger than the patients [84], yet there is an 
inherent imbalance between the researcher and the researched in qualitative health 
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research [85]. The interviewer was familiar with and fond of talking to older adults, 
and conscious of creating a secure environment for answers and thoughts. On the other 
hand, this background might have led to fear of making the interviewee 
uncomfortable, and hesitation in asking excessively personal questions. Although the 
interviewer was inexperienced, her self-confidence grew during the interviews [57], 
but the first interviews probably had lower quality than the later ones. One of the 
patients had reduced cognition and the interviewer tried to compensate by asking 
follow-up questions to clarify the patient’s experience. This interview was less rich 
with fewer descriptions, and the patient’s cognitive impairment probably influenced 
the answers. None of the patients in this study had a MMSE below 25. For all patients, 
more exploratory questions were asked if the interviewer doubted whether the patient 
had understood the question. We considered this validation during the interviews to be 
sufficient and did not perform member checks (return transcriptions to participants to 
provide feedback on the findings) or repeated interviews, which would have risked 
burdening patients without necessarily increasing validity [86]. However, we might 
have missed the opportunity for an even more nuanced description from the patients’ 
point of view [62]. Research conducted in one’s own practice raises some concerns, 
and the interviewer working in the cardiology unit and being a colleague of the 
interventional cardiologists might have led to less exploration of patients’ negative 
experiences of the decision-making process [87]. We did not use the words trust or 
autonomy in the interview guide, yet experiences of trust and of being autonomous 
were frequently reported and thus further interpreted. The interview guide being in 
plain language might have reduced deeper reflexions on autonomy and trust. However, 
our aim was for all the patients to understand the questions, and we received varied 
descriptions. After the first two interviews we expanded the interview guide to obtain 
more precise descriptions of why the patients wanted the procedure, how they 
preferred to receive risk information and how they faced challenges. This flexible 
approach with stepwise analysis during data collection and modification of the 
interview guide is recommended in qualitative research in order to sharpen one’s focus 
and aim [60]. The planning of the study and the data collection and analysis were 
performed by doctors not trained in philosophy, and this affected the process, aiming 
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for clinical implications of the results rather than in-depth philosophical analysis. We 
were inspired by O`Neill [64] and Dodds [65] in our focus on trust and autonomy, 
including relational aspects. Validation of the analysis and presentation was 
strengthened by several of the research team not being involved in the TAVI 
treatment, bringing external perspectives to the data collection and findings.  
 
5.1.2 External validity  
External validity is defined by asking in what context the findings can be applied [55]. 
Qualitative research aims for transferability, i.e. to outline the situations in which the 
findings might provide valid information, as opposed to generalization in quantitative 
research [55]. We included a purposive sample of patients as described under sample 
size in order to increase transferability [55]. However, our sample contained elective 
TAVI patients from a single hospital, and the majority were intermediate or robust on 
a physical frailty score and other patterns may have been revealed in a frailer group. 
We interviewed patients who were accepted for TAVI, and the results are probably not 
transferable to decision-making in older patients in general, and we might have 
obtained different descriptions had we interviewed the patients before the procedure or 
before the decision was made. The interventional cardiologists assess patients’ lease 
on life before offering treatment, and TAVI patients might be psychologically more 
robust than their peers. However, since there are strict selection criteria for TAVI and 
the majority of candidates are older than 70 years, our findings may be relevant to 
patients accepted for TAVI in other countries [1].  
Hospital treatment in Norway is provided through the public health care system and 
there are no financial incentives for cardiologists to perform TAVI. Studies have 
revealed that in the Nordic countries people trust public authorities [88]. There were 
only white participants in our study, and most were Christians. The results may 
consequently not be transferable to diverse cultural and religious contexts. 
 
5.1.3 Sample size 
The sample size was guided by the concept of information power, i.e. “the more 
information the sample holds, relevant for the actual study, the lower amount of 
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participants is needed” [83]. The study aim narrowed from the more general “patient 
perspective and decision-making prior to TAVI” to a focus on the “conditions for an 
autonomous choice”. All patients in the interview study had already been included in 
the quantitative study, meaning that the baseline characteristics were known to the 
researcher. The investigator introducing herself as a researcher and a geriatrician 
probably increased the likelihood of patients accepting the invitation, and also the fact 
that they were offered home interviews when it suited them increased participation. 
We included TAVI patients over 70 years with variations in complications, age, 
gender and level of physical frailty, ensuring strong specificity. At the outset we did 
not have a strong theoretical framework; however, during the interviews and analysis 
process we applied the theory of “shared decision-making” and “autonomy”. Most 
interviews were rich, where patients elaborated on the questions in the interview guide. 
We focused on in-depth analysis from a few selected patients and did not seek to cover 
the whole area of decision-making before TAVI.  We do not exclude that interviewing 
more patients would have provided even greater knowledge. However, after four 
rounds of stepwise, cross-case analysis, adding two or three interviews at a time, the 
data were assessed as sufficient to answer the research question when we had included 
ten patients.  
 
5.1.4 Reflexivity 
The question is not if but how the researcher will influence the qualitative research 
process, in relation to transparency [55]. Objectivity in qualitative research means 
recognizing that knowledge is partial and situated, accounting adequately for the effect 
of the researcher, and realizing that subjectivity will occur when the effect of the 
researcher is ignored [55]. For a geriatrician in the Department of Heart Disease, it 
became a challenge to deal with the oldest patients and decision-making before 
procedures in general. The balance between overtreating and undertreating was of 
concern, and TAVI being a new treatment aroused curiosity about the decision-making 
process preceding the intervention. The vulnerability of cognitively impaired patients 
in decision-making became clear after working with patients with moderate to severe 
dementia for some years in a nursing home and an old age psychiatric hospital, as well 
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as seeing patients with dementia at the local hospital as part of the programme in 
geriatric medicine.  
The supervisory team included a former interventional cardiologist, a geriatrician and 
a junior doctor specializing in cardiology and thoracic medicine. Before starting this 
study, we were uncertain as to whether patients felt they had a choice or just passively 
accepted the offer of TAVI. Several issues could compromise decision-making: a busy 
department with little time for complex information, junior doctors with limited 
experience with TAVI assessing the patients, and the fact that diagnosing a severe 
valve disease will often make clinicians keen to “do something”, rather than focusing 
on patient choice. We were uncertain whether the patients were informed of rare, but 
severe complications of TAVI, such as stroke and death. There was no written 
information for patients prior to TAVI at the time of this study. The wish to illuminate 
these issues was the driving force and motivation for conducting the studies included 
in this thesis. 
 
5.2 Methodological aspects (studies 2 and 3) 
5.2.1 Study design 
We chose a single-centre prospective observational cohort study design for papers 2 
and 3 and will discuss potential weaknesses of this design in the following [89]. 
 
All patients in the study underwent TAVI, and the procedure was described in the 
patient record. For paper 2 the primary outcome was two-year all-cause mortality. All 
deaths are automatically registered in the patient’s medical record and no patients were 
lost to follow-up for the primary outcome, reducing risk of information bias. For paper 
3, accuracy regarding death was as in paper 2. As for the NYHA classification, 
previous studies have shown low inter-rater reliability and results must be interpreted 
with caution [90]; however, our results are in line with other TAVI studies 
demonstrating significant symptom improvement [91, 92].  
 
We did adjust for confounding factors based on literature in developing the frailty 
score, and adjusted for age, gender and logistic EuroSCORE, but hidden confounders 
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might have been present. We found a satisfactory internal consistency for NEADL in 
study 3, with Cronbach`s alpha of 0.87 at baseline and 0.86 at six months.  
 
Selection bias refers to the study population failing to mirror the target population of 
interest. Our studies were performed in the early era of TAVI, when more robust older 
adults may typically have been referred, but this is unknown. Patients in long-term 
nursing home care or patients with advanced dementia have not been offered TAVI in 
Norway, so the frailest group of patients with aortic stenosis is not included. The most 
robust older adults with aortic stenosis were offered SAVR at the time of this study 
[1].  
 
Among 166 patients qualified for inclusion in study 2, ten refused to participate, seven 
were not included due to logistical reasons and two cases were not elective treatment. 
The patients not included for logistical reasons were probably missing completely at 
random. For the ten patients who refused to participate and for the two treated acutely, 
this might not have been the case. The patients who refused were not asked to give a 
reason, but some said they were too tired to complete the tests, and they might have 
been frailer than the included patients. We conclude that there is a risk of missing not 
at random in the study, and we are aware that the population does not include all 
patients ≥70 years with severe, aortic stenosis; however, there was a high inclusion 
rate, at 89% of eligible patients, and we consider the study to have good external 
validity. We collected a large number of variables and had comprehensive information 
on the patients, which increased internal validity.  
 
5.2.2 Power calculations 
Estimation of sample size was based on the PARTNER cohort B study [3] reporting 
one-year mortality of 30.7% in the TAVI group, and a high rate of complications, 
estimated at 40%. We expected a lower rate of complications among fit patients (20%) 
and a higher rate among frail patients (55%), based on previous studies in different 
patient populations [45, 93]. With power of 80% and a 5% level of significance, we 
needed 35 patients in each of the fit and frail groups. Most patients are intermediate. 
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With 25% of patients in each of the fit and frail groups, and 50% in the intermediate 
group, we needed 140 patients. We expected only a few drop-outs because the baseline 
examinations were not too challenging, and follow-up telephone interviews were at six 
months. Based on this we included 5% more, thus a total number of 147 patients. In 
our material, we found a significantly lower event rate than expected from the 
PARTNER cohort B study, and the basis for our power calculation may thus have 
been weakened. We therefore did not perform a power calculation for paper 3, which 
is a limitation of this study, and consequently we may have overlooked potential 
positive relations. Subgroup analysis to examine whether frail patients had more 
complications, as expected from other studies [94], showed overlapping confidence 
intervals, supposedly due to lack of power. 
 
5.2.3 The cost of dichotomizing continuous variables 
We chose to present the frailty score as a dichotomized variable. This is common in 
clinical research, since it is helpful to label individuals as having or not having a 
quality and it simplifies the analysis and makes it easier to interpret and present the 
results [95]. However, it comes at a cost of loss of information and reduces the 
statistical power to detect a relationship between the variable and patient outcome. It 
also increases the risk of a positive result being a false positive and there might be 
extensive variability within each group. Individuals close to, but on opposite sides of, 
the cut-off point are categorized as being very different rather than very similar [95]. 
The frailty score is therefore also presented as a continuous variable.  
 
5.2.4 Cut-offs for variables in the novel frailty score 
When developing the frailty score, we also dichotomized the different variables in the 
score (except for MMSE, where we used three categories), risking loss of information 
as mentioned above. However, by using cut-offs from previous research we 
diminished the risk of a data-driven analysis and increased power.  
In order to separate better, we chose to have three categories for MMSE. The cut-off 
of <20 was chosen because this might distinguish between mild and moderate 
dementia [31, 96], and it has also been predictive of decision-making capacity [31]. 
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We chose a high cut-off for normal cognition of ≥27, because this was used in a 
previous TAVI study [47], and because we assumed that some of the patients would 
have a high level of education, and we wanted to reduce the risk of false positive 
results [97]. MMSE is affected by age and educational level and the results must 
therefore be assessed with caution [98].  
We measured instrumental activities of daily living with the Nottingham Extended 
Activities of Daily Living scale (NEADL) [99]. Based on clinical experience, we 
postulated that most patients accepted for TAVI would be independent in basic 
activities of daily living, and chose a scale measuring activities beyond basic self-care 
skills, in order to distinguish better between patients. The four subsections, mobility, 
kitchen, domestic and leisure may be added to an overall score [66]. To simplify 
implementation in clinical practice we chose a cut-off for NEADL of a score below 44 
indicating dependence in at least one instrumental activity of daily living. The 22 items 
are scored on a four-point scale ranging from 0=not at all, 1=with help, 2=on your own 
with difficulty, 3=on your own, and a summary score (range 0-66) is generated. 
Previous research has used a cut-off of >43 for classifying a patient as fit [45, 100]. 
Reduced cognition might affect how patients recalled their performance of different 
activities and NEADL must therefore be interpreted with some caution due to recall 
bias. A lower cut-off for NEADL would probably be preferable to increase the 
sensitivity of the novel frailty score, but no such cut-off has been described, and we 
chose not to examine the dataset to find the best cut-off, risking a data-driven analysis. 
One study of stroke patients reported a valid and reliable change if the NEADL 
improved or deteriorated by 4.9 points or more, and clinically important if the mean 
change score was in the range from 2.4 to 6.1 points after treatment [101].  
Body Mass Index (BMI) is frequently used as a screening for malnutrition. There are 
different cut-offs of BMI to identify risk of malnutrition. We chose a cut-off at BMI 
<20.5 kg/m2 from Nutritional Risk Screening 2002 (NRS 2002), because it is a 
validated score [102], and mandatory at Haukeland University Hospital, where it is 
included in the patient’s electronic record, thus increasing the feasibility of 
implementing a frailty score in clinical practice [103]. For 82 patients we only have 
self-reported height, but a Swedish longitudinal study has revealed only a small 
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misclassification bias between self-reported and measured height in older adults [104], 
and due to small cultural differences between Norway and Sweden, we would expect 
similar findings in Norway. Nutrition was also assessed by responses to the question 
“Have you lost weight during the past year?” This is a modification of the original 
Study of Osteoporotic Fracture (SOF) frailty index; in the original index they stated 
that weight loss of ≥5% between the third and fourth examinations (mean 2.0 (SD 0.3) 
years between examinations) was significant. Since we only had baseline data, we 
used self-reported weight loss, as this has been used in other studies [105]. We 
assigned one point for each of the three dimensions in SOF to arrive at the score [67]; 
however, we did not use the cut-off in the original paper (≥2 points=frail) since we 
used it as part of the total score.  
For the Charlson Comorbidity Index, we chose the cut-off of ≥3 as recommended 
when the mortality of the disease under study is high [106]. We chose the Charlson 
Comorbidity Index because it is less time-consuming than other comorbidity scores, 
such as the Cumulative Illness Rating Scale [107], thus increasing applicability in 
clinical practice.   
 
5.3 Discussion of main results  
The European Society of Cardiology recommends a thorough selection of patients and 
an objective assessment of frailty before TAVI. However, there are no clear cut-offs or 
agreement about when the procedure might be futile. The aim of this thesis was to 
provide data to inform the decision-making process when choosing between TAVI and 
conservative treatment, by assessing patients’ experience of autonomy, the predictive 
value of a frailty score and examining baseline frailty including cognition and 
outcomes of importance.  
 
5.3.1 Benefit and risk 
Natural course of aortic stenosis – difficult to prognosticate  
Severe, symptomatic aortic stenosis has a poor prognosis without valve intervention. 
However, few studies focus on the natural course of AS, and most of them are small, 
retrospective studies [4, 108, 109]. The classic study of Braunwald and Ross from 
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1968 was an autopsy study based mainly on studies before 1955 (before 
echocardiography was used in diagnosis), and the number of patients included in the 
study is not accounted for [110]. Different studies find different survival rates, and the 
2012 ESC guidelines state: “As soon as symptoms occur, the prognosis of severe AS is 
dismal, with survival rates of only 15-50% at 5 years” [111]. In one of the papers 
referred to, the author states that severe aortic stenosis with no or mild symptoms 
(NYHA I and II) has a better long-term prognosis with a five-year survival of 76% [4]. 
The guideline recommends valve implantation when symptoms occur, irrespective of 
severity [1].  
 
Selective survival after TAVI?  
In the PARTNER study cohort B, 358 inoperable, symptomatic patients with severe 
aortic stenosis were randomized to TAVI or “standard care”, which often included 
balloon aortic valvuloplasty. At two-year follow-up, 43% in the TAVI group and 68% 
in the “standard therapy” group had died, while 83% of survivors in the TAVI cohort 
and 43% in the standard therapy cohort were asymptomatic or had mild symptoms 
(NYHA I or II) [91]. The authors suggest that the mortality benefit after TAVI may be 
limited to patients who do not have extensive coexisting conditions. A systematic 
review of long-term follow-up after TAVI including 13 857 patients, mean age 81.5 
(+/- 7 years), found survival at 1, 2, 3 ,5 and 7 years to be 83%, 75%, 65%, 48% and 
28% respectively, and lower than the actuarial survival of 82-year-olds [112], as 





Figure 3: Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 
five-year survival and beyond, Vol 6, No 5 (September 2017), permission conveyed through Copyright 
Clearance Center, Inc. Used with permission of AME Publishing Company, from Annals of 
Cardiothoracic Surgery [112]. 
 
The Norwegian Registry of Interventional Cardiology report from 2018 states that 
three-year mortality after TAVI is 20% in Norway [54]. Another systematic review 
[113] found only two studies on the comparison of TAVI with medical therapy. One of 
them was the previously mentioned PARTNER cohort B. The other was a 
retrospective propensity-matched study of 270 patients, with 135 patients in each 
group. At two-year follow-up, 30% in the TAVI group and 59% in the medical group 
had died. It is well-documented that TAVI provides survival benefit and improvement 
of symptoms, as our study confirms. However, uncertainty remains as to whether 
patients with mild symptoms have the same poor prognosis as those with more severe 
symptoms. This could be of importance for frail patients with mild symptoms when 
there is doubt about the benefit. The favourable survival rate after TAVI appears not to 
be valid for all patients. 
 
Endocarditis 
We found a higher frequency of infective endocarditis (IE) than expected. In a recent 
meta-analysis with a mean follow-up at 3.4 years, the overall incidence of IE in TAVI 
was 2.0% [114]. In paper three, five of six patients with IE had a pacemaker or an 
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implantable cardioverter defibrillator, which might be linked to an increased risk of IE 
[115]. Several single-centre studies finding higher incidences suggest that IE is 
underreported in large studies and registries [116, 117]. Diagnosing endocarditis is 
challenging, and the presentation might be atypical since the patients are old with 
comorbidities [114]. As endocarditis can occur later on, longer follow-up than one 
year seems significant. Antibiotic prophylaxis during the TAVI procedure was 
administered to all patients. At discharge, the patients and their general practitioners 
were informed routinely about the risk of endocarditis and indications for prophylaxis. 
Pacemaker implantation was higher in this early period of TAVI treatment, where 39% 
of the patients received a new pacemaker during the hospital stay. The Norwegian 
Registry of Interventional Cardiology [54] reported 18% pacemaker implantation after 
TAVI at Haukeland University Hospital in 2018.  
 
Symptom improvement and maintenance of extended activities of daily living 
We found a substantial improvement in NYHA class from baseline to six months. 
Based on the improvement of symptoms we expected to find an improvement in 
NEADL. However we found no change in mean NEADL. There was variation on an 
individual level. Some patients improved in independence and others deteriorated, 
although for most patients, the change in NEADL was minor. This was not due to a 
floor or ceiling effect, since only a few patients had the maximum score, and none had 
the lowest score. Other factors such as frailty and dementia probably have more impact 
on level of independence than the aortic stenosis per se and six months follow-up is 
probably too short to establish deterioration due to other causes [118]. In a study of 
patients before and after hip replacement, the NEADL was insensitive to change with 
poor effect sizes compared with other scales of health status. Being designed to assess 
the wide range of disabilities seen after a stroke, the NEADL has quite large distances 
between each of the points on its scale, making it more difficult to register 
improvement [119]. There was no difference between the frail and robust patients 
regarding change in NEADL from baseline to six months. Given its previously 
mentioned limitations, the present study suggests that patients should be informed that 
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most patients are likely to maintain their functioning in activities of daily living six 
months after TAVI. 
 
Frailty assessment and suggestions for cut-off values  
As presented in the introduction, frailty adds information to risk assessment in older 
TAVI patients, where frail patients have a higher risk of morbidity and mortality [38, 
52]. Data from the UK TAVI registry indicated that frailty was associated with lower 
observed survival following TAVI as shown in Figure 4:  
 
 
Figure 4: Kaplan-Meier plots across Canadian Study of Health and Ageing (CSHA) estimated frailty 
(top left), KATZ activities of daily living dependency (top right), physician-estimated poor mobility 




In a recent single-centre prospective observational study (n=246) by Kim et al. [94], 
preoperative geriatric assessment was performed before intervention for severe aortic 
stenosis. The authors identified five trajectories based on a frailty index, suggesting 
that functional decline or lack of improvement is common in older adults with severe 
frailty undergoing TAVI or SAVR. In our study, patients characterized as frail had a 
significantly higher all-cause mortality after two years compared with robust patients. 
Despite this, we were not able to identify different trajectories in the surviving patients 
based on frailty score, and there was no difference in mean NEADL at baseline and six 
months. There is no agreement on cut-off values for frailty in TAVI. A recent position 
statement from the Canadian Cardiovascular Society (CCS) describes severe frailty 
and states that the following are risk factors for futility: A - advanced dementia, B - 
bedbound, not mobile, C - cachexia or severe sarcopaenia, D - disability for all/most 
ADLs, E - end stage renal, liver, lung or malignant disease [121]. Patients with severe 
frailty (A-D) as described in the CCS statement will have a life expectancy < 1 year. 
The implication of this statement in regard to futility is of uncertain clinical relevance, 
since these patients are indisputably too frail for TAVI and would not be offered this 
treatment in the first place. In contrast, the 2017 ACC Expert Consensus Decision 
Pathway for TAVI describes patients where benefit/risk in TAVI is uncertain. They 
recommend a functional assessment including frailty and a more detailed investigation 
with regards to futility if gait speed is <0.5 m/s or <0.83 m/s with disability/cognitive 
impairment, BMI < 21 kg/m2, albumin <3.5 mg/dl, <10 pounds weight loss in past 
year, mini nutritional assessment ≤ 11, 6 min walk <50 m or unable to walk, dependent 
in ≥1 activities, MMSE<24, depression history or positive screen, < 1 year life 
expectancy or survival with benefit <25% at two years [20].  
In a recent qualitative review on patients’ experiences of TAVI, the authors found that 
patients with slow or no symptom improvement and/or long hospital stays after TAVI 
had difficulty in reconciling their expectations with their actual experience. The impact 
of comorbidities on their health and lives became clearer after TAVI amongst those 
whose expectations were not met [122]. In study 2,  >70% of the patients regarded as 
frail survived for two years, and in study 3 most patients had symptom improvement 
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after six months. We therefore cannot argue for a strict cut-off for when it should be 
recommended not to offer TAVI based on the frailty score alone. However, the frailty 
score will identify patients where TAVI might be futile, and discussing the scoring 
may enhance shared decision-making by displaying increased risk of worse outcome. 
 
Quality of life 
In this thesis we chose to focus on functional status measured by NYHA class and 
have not assessed quality of life in a broader perspective. Previous studies have 
addressed this topic. A systematic review on functional status and quality of life after 
TAVI [123] found substantially improvement of NYHA class and other disease-
specific measures.  Despite this, overall quality of life improved to a lesser degree and 
the change was not always regarded as clinically important. This has later been 
confirmed in another systematic review [124].  
 
5.3.2 Shared decision-making, autonomy and trust 
Shared decision-making 
In situations where doubt prevails regarding benefit, shared decision-making and 
exploring patient preferences are even more important. A systematic review on patient 
values and preferences regarding AS valve replacement was published in 2016 [125]. 
The authors found two studies eligible for review. The first revealed that patients were 
willing to tolerate high mortality risk in order to achieve full health [126]. The second 
study found that patients’ decision-making involved several concerns, including 
symptom burden, a trusting relationship with their doctor and obligations to family and 
caregivers [127]. 
A qualitative study examined patient-defined goals in older adults facing treatment 
decisions for severe aortic stenosis [128]. This study found that patients emphasized 
the ability to perform a specific activity and maintaining independence as the most 
important goals of treatment. 
Another qualitative study examined patterns in patients’ decision-making process and 
found variation in that some patients left the decision to others, some were unsure if 
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they wanted the procedure, while others had reached a point where they were certain 
that they wanted the procedure [129]. 
For patients receiving medical treatment, a study from 2017 [130] found that doctors 
reported patient preference as the most common reason for medical AS treatment. 
However, patients felt that their heart valve doctor involved them to a lesser extent in 
treatment decisions than patients accepted for SAVR or TAVR. The authors conclude 
that there is “a potential gap in care that may benefit from additional efforts to enhance 
communications between patients and doctors”. 
 
The 2017 ACC Expert Consensus Decision Pathway for TAVI [20] emphasized shared 
decision-making, and that patient expectations and goals should be established early in 
the process in the context of a discussion on life expectancy, expected improvement in 
symptoms or survival, and end-of-life constructs. The authors argued that this enabled 
an exchange about the promise of TAVI as well as the realities of advanced age, 
alternatives to intervention and palliative care options. The statement from the 
Canadian Cardiovascular Society also highlights shared decision-making through 
incorporation of patients and their preferences, and suggests the implementation of 
shared decision-making tools, such as the American College of Cardiology Aortic 
Stenosis Choice [121]. A recent summary from the American Geriatrics Society 
provides a framework for care of older adults with multiple chronic conditions. They 
recommend recognizing the limitations of the evidence base and identifying patients’ 
health priorities and incorporating these into decision-making [131], especially where 
there is uncertainty as to whether disease-specific guidelines are applicable. This is 






Figure 5: Decision-making and care of older adults with multiple chronic conditions. The Multiple 
Chronic Conditions Action Steps facilitate decision-making in the face of uncertainty of disease 
guideline‐driven decision-making for the large segment of older adults with increasing numbers of 
chronic conditions and functional limitations. Reproduced with permission from the Journal of the 
American Geriatric Society. © 2018. The American Geriatrics Society [132]. 
 
Autonomy 
A core element of shared decision-making is respecting patients’ autonomy. 
Beauchamp and Childress’ seminal book “Principles of Biomedical Ethics” [26] 
presents the four principles of bioethics: autonomy, non-maleficence, beneficence and 
justice. In order to behave autonomously, one must act with intention, understanding 
and absence of controlling influences [26]. Critics have argued that the concept of 
autonomy used in bioethics is too narrow [64, 65]. It overlooks the social settings and 
power relations that affect the context of a choice. It is difficult to choose 
autonomously in the limited (rationalistic and individualistic) version of the concept 
when one is ill and vulnerable. A relational understanding of autonomy recognizes that 
decisions do not take place in isolation or full independence, and patients trusting their 
doctor might still make an autonomous choice, as our findings indicate [65]. Shared 
decision-making might conceal the power asymmetry, with an illusion that it supports 
a dialogue between equals, but underestimate the fact that doctors’ medical knowledge 
gives them power [84]. In a complex clinical setting, it is important to identify and 
respect the patient`s degree of autonomy and to be aware of paternalistic attitudes 
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among health care professionals when providing care in the best interest of the patient 
[25]. Physicians should enhance patients’ autonomous capacity by understanding their 
experience and emotions in a broader way, being aware of power, trust, scientific 
uncertainty, vulnerability, agency and responsibility [133], as shown in Figure 6:  
 
 
Fig. 6. Illness and shared decision-making as an existential journey. Illness may (temporarily) reduce 
the healthy person’s autonomous capacity (solid arrow). Shared decision-making, depending on its 
quality, has the potential to restore this autonomous capacity (the goal) (upper dotted arrow) but also 
to further reduce it (lower dotted arrow). The ellipse depicts the consultation. We have not provided 
arrows to suggest whether power, trust, etc. will restore or reduce the patient’s autonomous capacity, 
because we think this could vary with the situation, people involved, and how shared decision-making 
is performed. Studies are needed to explore these proposed effects [133]. Reprinted with permission 
of Copyright Clearance Center. All rights reserved 
 
In our study, TAVI patients expressed self-empowerment and claimed it had to be 
their decision. Yet some chose the intervention as an obligation to their family or 
passively accepted it. This substantiates the importance of illuminating all aspects of 






Patient involvement and doctors’ respect for patients’ values and beliefs are vital to 
medical decisions, but  the concept of shared decision-making has limitations [64]. For 
instance, to list all imaginable side effects may disturb a patient who definitely wants 
to be treated and understands that there are risks associated with accomplishing that 
goal [65]. Our study reveals ambivalence towards knowing the most feared 
complications and at the same time needing to feel safe. O`Neill argues that a strong 
focus on autonomy might fail to secure trust: “Trust belongs with relationship and 
(mutual) obligations; individual autonomy with rights and adversarial claims” [64]. 
We found that trusting doctors is a core element of decision-making, and this puts 
patients at the mercy of doctors’ power [84]. However, in the present study, patients 
did not blindly trust their doctors and wanted a second opinion if not reassured. 
Skirbekk describes this as mandates of trust, where patients consider appropriate 
restrictions to the doctors’ judgement [134]. Not all patients desire to participate in the 
decision-making process to the same degree [135-137], and shared decision-making 
emphasizes including “the patient in the decision-making to the extent that they 
desire” [138]. Safeguarding patients’ rights might therefore be in opposition to shared 
decision-making. A Norwegian study of doctor-patient conversations prior to high-risk 
cardiac procedures revealed a deep confidence in the doctors’ ability to get them 
through the treatment they were facing, yet the obligation to make the decision was 
mutual in an asymmetrical power relationship [139].  
 
5.3.3 Vulnerable autonomy and the impact of cognitive impairment and 
dementia 
For patients with cognitive impairment, the concepts of autonomy and shared decision-
making are even more challenging. In the qualitative study, only one patient presented 
signs of cognitive impairment that might have affected the decision-making process. In 
study 3, 15 patients (18%) had an MMSE below 24, indicating possible dementia.  
The prevalence of dementia in Western Europe rises exponentially with age, from 
4.3% among 70 to 74-year-olds to 43.1% in the 90+ population [30, 140], although 
more recent studies find a lower age-specific incidence [141]. In the Swedish TAVI 
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registry, the average age for TAVI patients is about 82 years [142]. Dementia will 
eventually diminish a patient’s ability to make an informed choice. It is recommended 
to assess cognition with standardized methods before TAVI, to have a baseline 
measure in case of procedure-related deterioration and to weigh risk, benefit and cost-
effectiveness carefully [23]. Since TAVI is a procedure with a risk of complications, 
family wishes alone should not be sufficient for performing the intervention. Curing 
aortic stenosis in order for patients to survive to end-stage dementia raises ethical 
questions, and even if this is what the family wishes, it might not be what the patient 
would want if he or she could act autonomously. These are difficult issues to discuss 
with patients with dementia and their families, both due to patients’ anosognosia (a 
physiological damage to the brain, where patients have no awareness of their disease) 
[143] and health care professionals’ fear of patients losing hope when focusing on the 
deterioration and increased dependence expected after a diagnosis of dementia [144].  
Cognitive decline leaves the patient more reliant on, and less capable of questioning, 
doctors’ advice. Beyond the challenges of patient autonomy, dementia decreases 
expected survival. In a recent study of >50 000 patients with dementia, mean survival 
time was 5.1 years in a cohort with mean age 81.1 years and mean MMSE 21 at 
diagnosis of dementia. Mean (interquartile range) survival time was related to MMSE 
score, with lower MMSE scores indicating lower survival. The lowest expected 
survival in patients with MMSE 0-17 points was 3.0 years (1.5-5.1) in men and 3.7 
years (1.9-6.2) in women. The average 80-year-old in Sweden has a life expectancy of 
nine years, including a significant proportion of people with dementia. Survival for 
those who do not develop dementia is expected to be even longer [145]. Other studies 
have confirmed variety in progression of the disease, and demonstrate that in patients 
with Alzheimer’s disease about half of the patients have a slow progression [146]. 
Novel treatment opportunities raise new ethical dilemmas that we should discuss 
thoroughly to ensure that we do no harm. Advance care planning is recommended in 
order to provide high-quality care for patients with dementia. This is a dynamic, 
continuous process, in which early dialogue and reflection on patient preferences, 
including end-of-life care, are sought [147]. Starting the process at an early stage, 
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preferably before the diagnosis of dementia, may facilitate the transition to palliative 
care.  
 
5.3.4 Geriatric cardiology facilitating comprehensive decision-making 
Geriatricians are specialists in care for frail older adults and are able to evaluate 
coexisting geriatric syndromes and comorbidity, which makes them essential partners 
in the decision-making process prior to TAVI. End-of life planning and acceptance of 
the inevitability of death as part of the normal human life trajectory rather than an 
enemy to be avoided at all times can help relocate care decisions away from options 
that may no longer be useful or relevant [148]. A focus on patient preferences is not a 
specific task for geriatricians, but geriatricians are aware that care goals may change as 
people age. Thus, geriatricians’ approach to treatment dilemmas consists of seeking 
information about what matters most to the individual patient, being aware that 
guidelines are often based on younger patients with fewer comorbidities. Several 
publications recommend integration of geriatric assessment prior to TAVI, and the 
inclusion of geriatricians in the heart valve team [19, 23]. As demonstrated in this 
thesis, geriatricians can provide an objective assessment of frailty and also incorporate 
patient preferences in a situation of vulnerable autonomy, facilitating a tailor-made 





1. The study confirms the value of self-determination and autonomy in medical 
decisions, and adds to previous knowledge by providing empirically-based 
descriptions of what constitutes the conditions for TAVI patients’ autonomy as 
experienced in the decision-making process.  
 
2. We found that a frailty scale based on geriatric assessment predicted two-year 
mortality in TAVI patients beyond the established risk score.  
 
3. Patients had symptom improvement and could maintain activities of daily living six 
months after TAVI, and had low mortality after two years. Rarely, severe 
complications occurred, such as stroke and endocarditis. Some patients had cognitive 
impairment or dementia at baseline which might have influenced the decision-making 
process.  
 
This thesis provides support to identify patients with higher risk and lower expected 
benefit after TAVI, and circumstances under which the procedure might be futile. The 
decision to offer TAVI should be based on an analysis of benefit versus risk, taking 




7. Implications and suggestions  
7.1 Clinical practice 
Frailty screening should be performed in older adults before TAVI, and if the 
screening reveals possible obstacles to TAVI, a more thorough geriatric assessment 
should be performed. 
 
Doctors should be aware that older adults might have vulnerable autonomy, and the 
concept of shared decision-making could conceal the power asymmetry, where 
patients with cognitive decline and/or dementia are particularly vulnerable.  
 
In older adults with comorbid conditions, patients should be informed that TAVI 
might not solve all their health problems.  
 
7.2 Future research 
Further studies are recommended on risk versus benefit in patients where TAVI might 
be futile, and pre-TAVI decision aids should be developed to inform these patients and 
their families.  
 
Is frailty reversible in some patients after TAVI, and what are the characteristics of 
patients with dynamic frailty?  
 
Further studies are recommended on benefit versus risk in providing TAVI for patients 
with dementia. Complementary qualitative studies should be conducted involving 
health care personnel and older adults (including patients with dementia and their 
relatives) to explore attitudes to TAVI for patients with established dementia.  
 
Might geriatric assessment contribute to a sustainable health care system, by informing 
treatment decisions in the oldest population, not overtreating frail patients and not 
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Abstract 
Background  Patient autonomy is a leading principle in bioethics and a basis for shared decision making. This study explores condi-
tions for an autonomous choice experienced by older adults who recently underwent trans-catheter aortic valve replacement (TAVR). 
Methods  Qualitative study entailing semi-structured interviews of a purposive sample of ten older (range 73–89, median 83.5 years) adults 
after TAVR (median 23 days). The study setting was a cardiac department at a university hospital performing TAVR since 2010. Analysis 
was by systematic text condensation. Results  Even when choice seemed hard or absent, TAVR-patients deliberately took the chance of-
fered them by processing risk assessment, ambivalence and fate. They regarded declining the treatment to be worse than accepting the risk 
related to the procedure. The experience of being thoroughly advised by their physician formed the basis of an autonomous trust. The trust 
they felt for the physicians’ recommendations mitigated ambivalence about the procedure and risks. TAVR patients expressed feelings con-
sistent with self-empowerment and claimed that it had to be their decision. Even so, choosing the intervention as an obligation to their family 
or passively accepting it was also reported. Conclusions  Older TAVR patients’ experience of an autonomous decision may encompass 
frank tradeoff; deliberate physician dependency as well as a resilient self-view. Physicians should be especially aware of how older adults’ 
subtle cognitive declines and inclinations to preserve their identities which can influence their medical decision making when obtaining in-
formed consent. Cardiologists and other providers may also use these insights to develop new strategies that better respond to such inherent 
complexities. 
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1  Introduction 
From 2002, trans-catheter aortic valve replacement 
(TAVR) has been an option for patients with severe and 
symptomatic aortic stenosis and too high risk of open heart 
surgery. Typical TAVR patients are old and have significant 
comorbidities. While TAVR in general is better tolerated 
than surgery, it is still associated with complications,[1,2] and 
it is important that the patient understands risk and benefit 
for the procedure. 
Autonomy is a core element of shared decision making 
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(SDM), the preferred model for health care treatment deci-
sions. The purpose of SDM is to decrease the asymmetrical 
power between physicians and patients, by increasing pa-
tients’ information, sense of autonomy, and that treatment 
choices should reflect patient’s values and preferences.[3] In 
medical ethics, autonomy is understood as a “capacity for 
independent decisions and action”.[4] Beauchamp and Chil-
dress state three conditions for autonomy: intentionality, 
understanding and noncontrol, meaning intentionally as 
opposed to accidental and noncontrol as voluntariness free 
of both external and internal (for instance mental illness) 
control.[5] However, relational understanding challenges this 
definition of autonomy by stating “it ignores the social cir-
cumstances and power relations that affect choice con-
texts”.[6] In the elderly population, where medical decisions 
are more complex due to comorbidity and frailty, some stu-
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studies emphasize the importance of a trusting relationship 
with the physician.[7,8] As cognitive decline and dementia 
increase substantially with age, some patients have difficul-
ties giving informed consent.  
Patients’ decision to undergo TAVR assessment is mul-
tifaceted, and understanding their reasons for wanting to be 
treated and asking them to define their goals can enhance 
shared decision making.[9,10] Three patterns in TAVR pa-
tients’ decision making have been identified: the ambivalent, 
obedient and reconciled patient, highlighting that health care 
professionals should give tailored information based on 
patients’ values.[11] Patients’ need to discuss risks and bene-
fits of the treatment has also been emphasized. TAVR-pro-
grams have been developed to improve communication and 
provide decision support, including transition to palliative 
care.[12] Still, little is known about how patients experience 
autonomy preceding TAVR. 
As clinicians and researchers with extensive experience 
within geriatrics and cardiology, we wanted to address the 
special challenges for older TAVR patients examining their 
motivation for the procedure, risk perception, understanding 
of the procedure and ability of making an independent 
choice. The combination of advanced age and a busy hospi-
tal environment might challenge patient autonomy, and our 
preconception was that patients passively accepted the of-
fered treatment. Thus, our study explores conditions for an 
autonomous choice experienced by older adults who re-
cently underwent TAVR, with a special focus on relational 
and cognitive aspects.  
2  Methods 
We conducted a qualitative study based on semi-struc-
tured, individual interviews of TAVR patients.[13] This de-
sign is suitable to explore perspectives of human experi-
ences, motives, feelings, thoughts and values of major 
clinical relevance.[13] 
2.1  Study setting 
Participants in the study were enrolled post-procedure 
from a large university hospital in Norway with 860 somatic 
beds. The hospital has advanced interventional and surgical 
expertise, and has performed TAVR procedures since 2010. 
All patients were discussed in a heart team before the deci-
sion of offering TAVR treatment. Patients received infor-
mation from different physicians on the ward during the 
preprocedural hospital stay and from interventional cardi-
ologists performing TAVR the day before the procedure. 
Some patients also got information from their private con-
sultant cardiologists. There was no written information pro-
vided to the patient preceding TAVR at the time of this 
study.  
2.2  Data collection 
Interviews were conducted between February 2014 and 
April 2015. We searched for a purposive sample aiming for 
diversity regarding age, gender and complication rate. The 
inclusion criteria were patients over 70 years who under-
went TAVR; the only exclusion criterion was not speaking 
Norwegian. Inclusion was stepwise according to analytical 
strategy. The interviews lasted from 30 to 60 min and were 
conducted 2 to 4 weeks after TAVR, except for three pa-
tients who were interviewed after 9, 41 and 52 days due to 
either practical reasons or the analytical process. All inter-
views were audiotaped and transcribed verbatim by Skaar. 
Sample size was determined by the concept of information 
power and thus continuously evaluated as enrolment pro-
ceeded.[14] We had a narrow aim, dense specificity, applied 
theory and a strong dialogue. After four stepwise analyses 
adding two and three interviews at a time, the material was 
assessed sufficient to answer our research question accord-
ing to the mentioned criteria of information power when ten 
participants had been recruited. This does not imply that 
other phenomena could not have been discovered by further 
enrolment, but that the developed categories at that point 
were large and rich enough for thorough description of the 
experiences investigated. 
2.3  Participants 
Ten patients over 70 years were recruited, six were 
women. The characteristics of participants were list in Table 1. 
All underwent elective TAVR due to severe symptomatic 
aortic stenosis and high risk for complications to SAVR, but 
time to procedure varied from a few weeks after activity- 
induced syncope to several months with less dramatic 
symptoms. Logistic EuroSCORE varied between 8 and 28. 
One patient had mean pressure gradient of 39 mmHg, 
maximum jet velocity of 3.9 m/s and indexed aortic valve 
area for body surface area (BSA) 0.4 cm2/m2, the others 
fulfilled the echo cardiac criteria of severe aortic stenosis 
with mean pressure gradient over 40 mmHg, maximum jet 
velocity over 4.0 m/s and indexed aortic valve area for BSA 
below 0.6 cm2/m2. All ten patients had symptoms related to 
their AS. One of the patients had severe complications with 
cardiac arrest and stroke during the procedure; another had 
TAVR with direct aortic approach and was re-operated with 
open heart surgery two days after the procedure due to pro-
found bleeding.  
44 Skaar E, et al. Older adults’ decision-making regarding TAVR 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
Table 1.  Characteristics of participants. 
Men/Women 4/6 
Age   
7079 yrs 3 
8089 yrs 7 
Symptoms    
*NYHA I- II  1 
*NYHA II  7 
*NYHA III 2 
Syncope 1 
Angina 2 
#Logistic EuroSCORE  
< 10 2 
1020 7 
> 20 1 
Social status  
Live alone 5 
Comorbidities  
Coronary artery disease 3 
Chronic obstructive lung disease 2 
Diabetes 1 
Stroke or transitory ischemic attack 1 
Bypass graft surgery 2 
Peripheral vascular disease 1 
Renal failure 0 
Pulmonary hypertension 1 
Low ejection fraction (below 35%) 1 
Concomitant valve disease 3 
Education level  
Primary school 3 
High school 4 
College and/or university 3 
Cognition (prior to intervention)  
†MMSE NR > 27 6 
†MMSE NR 25–27 4 
Physical frailty  
§SPPB fit  3 
§SPPB intermediate 6 
§SPPB frail 1 
Post procedure pacemaker 3 
Severe complications 2 
Length of stay  
5 days 1 
6 or 7 days 6 
10 and 11 days 2 
17 days 1 
Discharged to   
Home 5 
Other hospital 1 
Rehabilitation 3 
Intermediate care 1 
*NYHA classification of the stages of heart failure, range from I-IV, most 
severe dyspnea at IV; #Logistic Euro SCORE is a model of predicting mor-
tality in high risk cardiac surgical patients; †MMSE-NR measures cognitive 
impairment, range from 0–30, higher score means better cognition; §SPPB 
measures physical frailty, higher scores better function. NYHA: New York 
Heart Association; MMSE-NR: Mini Mental Status Examination, Norwe-
gian Revision; SPPB: short physical performance battery. 
2.4  Ethical statement 
This study was approved from the Regional Committee 
for Medical Research Ethics 04.09.13, 2013/1310 REK. 
Informed consent was obtained from all participants.  
2.5  Analysis  
Qualitative analysis was performed in collaboration by 
Skaar and Schaufel following systematic text condensa-
tion,[15] proceeding through the following stages: (1) reading 
all the material to obtain an overall impression, bracketing 
previous preconceptions; (2) identifying units of meaning, 
representing different aspects of the patients’ experiences 
and coding for these; (3) condensing and abstracting the 
meaning within each of the coded groups; and (4) summa-
rizing the contents of each code group to generalized de-
scriptions and concepts reflecting the most important ele-
ments of autonomy reported. The interview guide consisted 
of questions addressing how patients experienced the proc-
ess preceding TAVR, focusing why they wanted the treat-
ment, how they coped with risk information and the chal-
lenge of making a choice. We used an editing analysis style 
where categories were developed from the empirical data, 
not in a theory-driven template analysis style from prede-
fined theoretical concepts.[16] Still, the analysis was in-
formed by theory of patient autonomy.[17] Analysis was 
done stepwise with new interviews supplementing the sam-
ple. A decision trail documented the choices during the 
analytical process.[18]  
3  Results 
Even when choice seemed hard or absent, TAVR- 
patients deliberately took the chance offered them by proc-
essing risk assessment, ambivalence and fate. They experi-
enced lack of a real sense of choice based on their condi-
tion’s severity and the risks presented to them, but regarded 
declining the treatment to be worse than accepting the risk 
related to the procedure. The experience of being truthfully 
and thoroughly advised by their physician formed the basis 
of an autonomous trust. The trust they felt for the physi-
cians’ recommendations and the copious information pro-
vided mitigated ambivalence about the procedure and risks. 
TAVR-patients’ striking self-determination comprised ex-
tensive mobilization of hope, lease of life and a robust sense 
of self. They expressed feelings consistent with self-em-
powerment and claimed that it had to be their decision. 
Even so, choosing the intervention as an obligation to their 
family or passively accepting it was also reported.  
3.1  Deliberately taking the chance  
Participants regarded declining the treatment to be worse 
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than accepting the risk related to the procedure. Based on 
information about symptoms gradually increasing and no 
hope for recovery without the procedure, the patient per-
ceived making a decision. None of them reported this as a 
difficult choice. Facing serious complications, they ex-
pressed that they could and had to deal with risk, since this 
to some extent is inherent in all medical procedures, and 
distanced themselves partly by thinking that “it happens to 
all others, but not me.” They regarded the intervention as 
routine, despite being aware of complications, and let fate 
decide. “It was not difficult at all to decide. I reckoned that 
if I said no, I wouldn’t live much longer.” (Mark). 
The majority experienced receiving good and well-ad-
justed amount of risk information, describing it as detailed 
and first-class. Even so, participants disclosed ambivalence 
regarding how much they wanted to know about complica-
tions. The importance of knowing the most dreaded com-
plications was highlighted, but simultaneously relief was 
expressed not being aware of these. One patient had denied 
risk information prior to an earlier procedure and still pre-
ferred it this way. Too much information regarding compli-
cations could induce anxiety and unnecessary worry, mak-
ing decision-making more difficult. One patient expressed 
fear ending up as a “vegetable” in a nursing home and be-
come dependent upon others. She worried life then would 
have little meaning. However, the participants imparted they 
were prepared to die, viewing death as a natural part of life 
and expressing an acceptance of fate. “I thought, I am 88 
years old and I will not live for a long time anyway. I am 
also a Christian, so I thought come what may, and then I 
didn’t ponder anymore.” (Molly).  
Some were afraid they would regret it if they declined 
and later on experienced more symptoms. They were aware 
that TAVR might not be an option later if they declined now. 
During the investigation period they realized that something 
had to be done, like a virtue of necessity. Thus, they barely 
experienced being in a situation where they should make a 
choice, and reported little doubt or anguish. One of the pa-
tients, who admitted to hospital after an exercise-triggered 
syncope, outlined how he did not specifically want the pro-
cedure, but was convinced he needed it. Another patient 
who had been physically active his whole life and now ex-
perienced fatigue and declining physical performance, ex-
pressed it like this: “In a way, you might say that I had a 
choice, however, I was rather determined to go through 
with the attempt to improve the situation with the operation. 
So it was not a difficult decision. (…)You're in a situation 
where you can make little difference, and you just have to 
resign and accept. (...) You never know when “fate strikes”, 
as we say.” (Colin). 
3.2  Autonomous trust in their doctors  
Our participants chose to follow the physicians’ treat-
ment recommendation seeking symptom relief and trusting 
the physicians with whom they were interacting. The par-
ticipants wished the physician to be honest and optimistic, 
still not concealing risk. Physicians spending time informing 
about the procedure and letting the patients take time to 
think it through, were cherished, as well as physicians rec-
ommending the procedure despite the risks. Patients ex-
pressed a general and strong confidence in GPs, private 
consultant cardiologists and hospital physicians. Even when 
the physicians described risks before surgery, it could not 
disturb the confidence and trust they also grounded in per-
sonal qualities of the physician. One patient expressed it like 
this: “I had confidence in the physicians because I noticed 
how they were as people. I have never been a fan of titles; I 
am much more reassured by people themselves, not their 
degrees or titles.” (Jennifer). 
The patients experienced lack of medical competence. 
When physicians recommended the treatment, patients 
trusted that the benefit outweigh the risk. This was illus-
trated by a female patient who explained how she would not 
have complained about the decision if she was denied 
TAVR, because she then reckoned that there was a good 
medical reason for not recommending her the treatment. 
Even when the procedure was thoroughly explained, they 
found it hard to understand and they trusted their physi-
cians’ medical competence: “Then I accept the treatment 
boldly, I trust the physicians, because medicine is so ad-
vanced now, that you don’t need to worry.” (Alice). 
However, the patients did not have blind trust in their 
physicians, the physicians had to act trustworthy or else the 
patients seek a second opinion. One patient was told by a 
physician that her heart was exhausted and there was noth-
ing more one could do. Immediately she went to her GP and 
asked him to send her to a cardiologist who referred her for 
TAVR. Another patient described that it was difficult mak-
ing a decision about TAVR following extensive risk infor-
mation where she felt the physician advised against the pro-
cedure, and said that it all resolved when she chose to rely 
on her private consultant cardiologist. This physician had 
spent time thoroughly explaining why he recommended the 
procedure, and she trusted him more than the risk informa-
tion of severe complications that she received at the hospital. 
So I went home and thought: “Should I do this or not, am I 
an idiot about to ruin my life?”, but then I considered all the 
others (physicians on the ward) who had said “go through 
with it” and my own physician recommending it.”(Anna). 
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3.3  Fundamental self-determination based on personal 
identity 
The participants in this study explicitly outlined how they 
made the decision on their own, and that this was important 
to them. This was expressed by a fundamental go-ahead 
spirit and strong lease of life when TAVR treatment was to 
be decided. They had a positive attitude towards themselves 
as robust and relatively strong, still acknowledging they 
were older and that their strength had declined. In general, 
TAVR candidates described themselves as feeling inde-
pendent and coping well. They did not want to be a burden 
to their relatives. Most did not involve the family in the 
decision, but informed them of their choice afterwards. A 
man expressed his independence in the decision making like 
this: “I told my wife that I had made the decision” …”After 
the decision was made, I didn’t reconsider, I slept well and 
didn’t worry. 
The TAVR-patients had a clear future goal of living 
longer and did not want to sit down waiting to die from aor-
tic stenosis when it could be cured by an operation. They 
aimed for improved body function, better health and quality 
of life. Describing lifelong patterns of an active life and 
having many interests, they wished to adapt to the adversi-
ties of aging like disease and poorer functioning as well as 
possible. The participants were not anxious, and universally 
expressed convictions to make the best of the situation: "I'm the 
kind of person who—when I have to do something—think that 
I just have to deal with it, and set my heart on it.” (Edna). 
Even if they considered the decision to be theirs, several 
highlighted that they felt an obligation to their relatives to 
accept a treatment that was recommended. One patient ex-
pressed how she did not want to let her children down if she 
died suddenly one day and they knew she could have had an 
intervention done to avoid it. Another patient took a more 
passive position during the decision-making process, possi-
bly due to mild cognitive impairment and depressive symp-
toms. She explained that she accepted TAVR mostly be-
cause her daughter wanted her to, and that she didn’t care 
too much herself: “We did not discuss it too much the phy-
sician and I either. (...) He just asked if I wanted (the treat-
ment) and I accepted. (…) I did it for the others’ sake as 
well.” (Rachel). 
4  Discussion 
Interviewing patients about the TAVR decision-making 
process, we found that despite being in a situation with lim-
ited choice, they claimed the decision to be their own. Trust 
in their physicians and their medical expertise was an im-
portant element for the decision. Below, we discuss the 
strengths and limitations of this study, and the impact of our 
findings.  
4.1  TAVR patients’ paradoxical autonomy 
This study confirms the value of self-determination and 
autonomy in medical decisions,[3,5,19] and adds to previous 
knowledge by providing empirically based descriptions of 
what constitutes conditions for TAVR patients’ autonomy 
experienced in the decision-making process. Older TAVR 
patients claim to make an autonomous decision, despite 
admitting profound trust in their physicians and revealing 
lack of medical competence. Cognitive decline leaves the 
patient more dependent and less capable to question physi-
cians advice. In the following, we will discuss the implica-
tions of our findings.  
Arguments that the strong focus on autonomy might have 
underestimated the significance of trust have been made, 
claiming it’s not true that “doctors offer patients a smor-
gasbord of possible treatments and interventions, a varied 
menu of care and cure”. By demanding informed consent, 
we make it possible to make an autonomous choice, but 
there is no guarantee.[4] Being ill and vulnerable makes it 
hard to choose autonomously. Some argue that focus on free 
choice, patient autonomy and informed consent might con-
ceal the power asymmetry, with an illusion that it facilitates a 
discussion between equals, but underestimate that the phy-
sicians’ medical expertise gives him/her power.[20] Our find-
ings show that trusting physicians is a core element of deci-
sion making, exposing patients to physicians’ power. How-
ever, this is no blind trust and these patients may seek a se-
cond opinion if they are not reassured by physicians’ advice. 
The philosopher Harald Grimen has outlined how diffi-
cult it is for the patient to challenge the authority of the phy-
sician, and “patients may be forced to trust what they 
get”.[20] This does not mean a return to paternalism. Patients 
being involved and physicians’ respect for patients’ views 
are essential to medical decisions, but the concepts of in-
formed consent and shared decision-making have limita-
tions.[4] A relational understanding of autonomy recognizes 
social circumstances and power relations. Autonomous de-
cisions do not happen in isolation or fully independence,[6,21] 
and patients trusting their physician might still make an 
autonomous choice, as our findings indicate. It is high-
lighted that in cases with a serious condition, no support in 
the decision-making may impede the patients’ capacity of 
making a decision. “A full listing of all possible side effects, 
for example , may well do nothing but agitate a patient who 
is clear that she desires to be treated and understands that 
there are risks associated with achieving that goal”.[6]  
There are cultural differences influencing decision- 
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making. In the USA where physician-patient interactions 
are regulated in detail by law, courts have ruled that for in-
vasive interventions physicians “need to discuss rare but 
serious risks, such as death and stroke”.[19] This secures 
patient rights, but might come at the cost of reduced trust in 
the physician-patient relationship. Not all patients wants to 
participate to the same extent,[22–24] and shared decision- 
making emphasize to involve “the patient in the decision- 
making to the extent that they desire”.[25] Securing patients’ 
rights might therefore be in conflict with shared decision- 
making. Our study illuminates the way ambivalence of 
knowing the most dreadful complications balances the need 
to feel secure. A Norwegian study of physician-patient dia-
logues preceding high-risk cardiac treatment demonstrated a 
profound confidence in the physicians’ ability to get them 
through the intervention or surgery they were facing, yet the 
responsibility making the decision was shared in an asym-
metrical power relation.[26]  
In our study, only one patient revealed signs of cognitive 
impairment that might have influenced the decision-making 
process. Executive cognitive impairment is subtle and pre-
valent among cardiac patients, and particularly impactful on 
the ability of the patients to make medical decisions like 
TAVR.[27,28] The prevalence of dementia in Western Europe 
increases exponentially with age, from 4.3% among 70–74 
years old to 43.1% in the 90+ population,[29] even if new 
studies find a lower age specific incidents.[30] In a Swedish 
registry, the average age for TAVR patients are about 82 
years.[31] Dementia will eventually diminish a patients capa-
bility of making an informed choice. TAVI frequently being 
provided to patients at high age ideally requires a cognitive 
assessment,[32] in order identify patients not capable of 
making an autonomous decision. TAVR being a procedure 
with risk of complications, family wishes alone are not suf-
ficient for performing the intervention. Curing aortic steno-
sis in order for patients to survive to end stage dementia also 
raises ethical questions, and even if this is what the family 
wants, it might not be what the patient would want acting 
autonomously. New treatment opportunities thus initiate 
new ethical challenges and we need to discuss implications 
thoroughly in order to do no harm.  
4.2  Validity and transferability 
A trained geriatrician, who is used to talk to and gather 
information from elderly patients, performed the interviews. 
The interviewer was a woman and younger than the patients, 
and most interviews were conducted in the patients’ own 
home. This reduced the asymmetrical power relation. As 
one of the patients had a cognitive impairment possibly af-
fecting her answers, the interviewer asked follow-up ques-
tions when in doubt. Disclosing both positive and negative 
aspects of the process they had been through, physicians 
they had met and their own reactions makes it likely they 
answered the questions in honest terms. On the other hand, 
the interviewer being employed at the department and 
knowing the interventional cardiologists, might have dimin-
ished exploring patients’ negative experiences.  
Our focus was not how the decision-making was per-
formed, but how patients experienced it. We therefore chose 
not to record and study the actual conversations between 
physicians and patient, but conducted an interview study. 
The analysis of trust focused on the participants’ general 
experience and did not discern differences regarding inter-
ventional cardiologists, private consultant or primary care 
physicians. Thus, the variability of physician types and the 
variability of interactions with patients have not been ex-
plored in this study, nor the complexity implicit in seeking a 
procedure. 
Our sample includes elective TAVR patients from one 
hospital, and the majority had an intermediate or fit frailty 
score. Other patterns may have been discovered in a frailer 
sample. 
Since we only interviewed patients who were accepted 
for TAVR, the results may not be transferable to deci-
sion-making in older patients in general. The interventional 
cardiologists assess lease on life before offering treatment, 
and TAVR patients are probably more physiological robust. 
However, since there are strict selection criteria for TAVR 
the majority of candidates are older than 70 years, our find-
ings may be applied to patients accepted for TAVR in other 
countries.  
Hospital treatment in Norway is funded through the pub-
lic health care system and provides no economic motives for 
cardiologists to perform TAVR. Studies have also shown 
that in the Nordic countries, people have a high level of trust 
towards authorities.[33] There were only white participants in 
our study, and most were Christians or non-religious. The 
results may therefore not be transferable to a different cul-
tural and religious setting. 
4.3  Conclusions 
Older TAVR patients’ experience of an autonomous de-
cision may encompass frank tradeoff; deliberate physician 
dependency as well as a resilient self-view. Physicians 
should be especially aware of how older adults’ subtle cog-
nitive declines and inclinations to preserve their identities 
can influence their medical decision making when obtaining 
informed consent. Cardiologists and other providers may 
also use these insights to develop new strategies that better 
respond to such inherent complexities.   
48 Skaar E, et al. Older adults’ decision-making regarding TAVR 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
Acknowledgements 
We would like to thank the participants in this study, and 
professor Kirsti Malterud for valuable comments. This 
study was mainly supported by Grants from Grieg Founda-
tion, Department of Heart Disease, Haukeland University 
Hospital and Kavli Research Centre for Geriatrics and De-
mentia, Haraldsplass Deaconess Hospital, Bergen. 
 
References 
1  Leon MB, Smith CR, Mack M, et al. Transcatheter aor-
tic-valve implantation for aortic stenosis in patients who can-
not undergo surgery. N Engl J Med 2010; 363: 1597–1607. 
2  Davies WR, Thomas MR. European experience and perspec-
tives on transcatheter aortic valve replacement. Prog Cardio-
vasc Dis 2014; 56: 625–634. 
3  Charles C, Gafni A, Whelan T. Shared decision-making in the 
medical encounter: what does it mean? (or it takes at least two 
to tango). Soc Sci Med 1997; 44: 681–692. 
4  O`Neill. In Autonomy and trust in bioethics; Cambridge Uni-
versity Press: New York, USA, 2002; 1–48. 
5  Beauchamp T, Childress J. In Principles of Biomedical Ethics; 
7th Edition; Oxford University Press: New York, USA, 2013; 
104–105. 
6  Mackenzie C, Stoljar N. In Relational autonomy; Dodds S, Ed; 
Oxford University Press: New York, USA, 2000; 213–235. 
7  Bastiaens H, Van Royen P, Pavlic DR, et al. Older people's 
preferences for involvement in their own care: a qualitative 
study in primary health care in 11 European countries. Patient 
Educ Couns 2007; 68: 33–42. 
8  Wrede-Sach J, Voigt I, Diederichs-Egidi H, et al. Decision- 
making of older patients in context of the doctor-patient rela-
tionship: a typology ranging from “self-determined” to “doc-
tor-trusting” patients. Int J Family Med 2013; 2013: 478498. 
9  Lauck S, Baumbusch J, Achtem L, et al. Factors influencing 
the decision of older adults to be assessed for transcatheter 
aortic valve implantation: An exploratory study. Eur J Car-
diovasc Nurs 2015; 1–9. 
10  Coylewright M, Palmer R, O'Neill ES, et al. Patient-defined 
goals for the treatment of severe aortic stenosis: a qualitative 
analysis. Health Expect 2016; 19: 1036–1043. 
11  Olsson K, Naslund U, Nilsson J, Hornsten A. Patients’ deci-
sion making about undergoing transcatheter aortic valve im-
plantation for severe aortic stenosis. J Cardiovasc Nurs 2016; 
31: 523–528. 
12  Lauck SB, Gibson JA, Baumbusch J, et al. Transition to pal-
liative care when transcatheter aortic valve implantation is not 
an option: opportunities and recommendations. Curr Opin 
Support Palliat Care 2016; 10: 18–23. 
13  Kvale S. In InterViews, an introduction to qualitative research 
interviewing; SAGE: Thousands Oaks, London, UK, 1996. 
14  Malterud K, Siersma VD, Guassora AD. Sample Size in Qua-
litative Interview Studies: Guided by Information Power. 
Qual Health Res. Published Online First: Nov 27, 2015. DOI: 
10.1177/1049732315617444. 
15  Malterud K. Systematic text condensation: a strategy for qua-
litative analysis. Scand J Public Health 2012; 40: 795–805. 
16  Crabtree B, Miller W. Doing qualitative research; 2nd Edition; 
SAGE: London, UK, 1999. 
17  Elwyn G, Frosch D, Thomson R, et al. Shared decision mak-
ing: a model for clinical practice. J Gen Intern Med 2012; 27: 
1361–1367. 
18  Whitehead L. Enhancing the quality of hermeneutic research: 
decision trail. J Adv Nurs 2004; 45: 512–518. 
19  Lo B. In Resolving Ethical Dilemmas, a guide for clinicians; 
Lippincott Williams and Wilkins: Philadelphia, USA, 2013. 
20  Grimen H. Power, trust, and risk: some reflections on an ab-
sent issue. Med Anthropol Q 2009; 23: 16–33.  
21  Entwistle VA, Carter SM, Cribb A, McCaffery K. Supporting 
patient autonomy: the importance of clinician-patient rela-
tionships. J Gen Intern Med 2010; 25: 741–745. 
22  Chewning B, Bylund CL, Shah B, et al. Patient preferences 
for shared decisions: a systematic review. Patient Educ Couns 
2012; 86: 9–18. 
23  Levinson W, Kao A, Kuby A, Thisted RA. Not all patients 
want to participate in decision making. A national study of 
public preferences. J Gen Intern Med 2005; 20: 531–535. 
24  Price EL, Bereknyei S, Kuby A, et al. New elements for in-
formed decision making: a qualitative study of older adults' 
views. Patient Educ Couns 2012; 86: 335–341. 
25  Edwards A, Elwyn G. Inside the black box of shared decision 
making: distinguishing between the process of involvement 
and who makes the decision. Health Expect 2006; 9: 307–320. 
26  Schaufel MA, Nordrehaug JE, Malterud K. “So you think I'll 
survive?”: a qualitative study about doctor-patient dialogues 
preceding high-risk cardiac surgery or intervention. Heart 
2009; 95: 1245–1249. 
27  Eggermont LH, de Boer K, Muller M, et al. Cardiac disease 
and cognitive impairment: a systematic review. Heart 2012; 
98: 1334–1340. 
28  Dickson VV, Tkacs N, Riegel B. Cognitive influences on 
self-care decision making in persons with heart failure. Am 
Heart J 2007; 154: 424–431. 
29  Prince M, Bryce R, Albanese E, et al. The global prevalence 
of dementia: a systematic review and Meta analysis. Alzheim-
ers Dement 2013; 9: 63–75. 
30  Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of de-
mentia over three decades in the Framingham heart study. N 
Engl J Med 2016; 374: 523–532. 
31  SWEDEHEART. Percutaneous Valve Registry, 2015. Http:// 
www.ucr.uu.se/swedeheart/67-swedeheart/english/169-swede
heart-annual-report-in-english (accessed Aug 14, 2015). 
32  Kappetein AP, Head SJ, Genereux P, et al. Updated standard-
ized endpoint definitions for transcatheter aortic valve im-
plantation: the Valve Academic Research Consortium-2 con-
sensus document. J Thorac Cardiovasc Surg 2013; 145: 6–23. 
33  Bergh A, Bjornskov C. Historical trust levels predict the cur-




A novel geriatric assessment frailty score
predicts 2-yearmortality after transcatheter
aortic valve implantation
Elisabeth Skaar1,2,3*, Leslie Sofia Pareja Eide4, Tone Merete Norekvål1,2,
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Aims Established surgical scores have limitations in delineating risk among candidates for transcatheter aortic valve im-
plantation (TAVI). Assessment of frailty might help to estimate the mortality risk and identify patients likely to




We conducted a prospective observational study in patients >_70 years referred for TAVI during 2011–15. A Heart
Team had declined the patients for open heart surgery due to high risk but accepted them for TAVI. Prior to the
procedure, a geriatric assessment (GA) was performed. Based on this, an 8-element frailty score with a 0–9 (least
frail–most frail) scale was developed. A total of 142 patients, 54% women, mean age 83 (standard deviation 4)
years, with severe and symptomatic aortic stenosis were assessed. All-cause 2 year mortality was 11%. The novel
GA frailty score predicted 2-year mortality in Cox analyses, also when adjusted for age, gender, and logistic
EuroSCORE [hazard ratio (HR) 1.75, 95% confidence interval (CI): 1.28–2.42, P < 0.001]. A receiver operating
characteristic (ROC) curve analysis indicated that a GA frailty score cut-off at >_4 predicted 2-year mortality with a
specificity of 80% (95% CI: 73–86%) and a sensitivity of 60% (95% CI: 36–80%). The area under the curve was 0.81
(95% CI 0.71–0.90).
...................................................................................................................................................................................................
Conclusion A novel 8-element GA frailty score identified gradations in survival in patients declined for open heart surgery.
Patients with higher GA frailty scores had significantly higher 2-year mortality after TAVI.
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The population of older adults is growing, and intrinsic susceptibility
to aortic stenosis is high with this new demographic scenery.
Improved decision making is necessary for the expanding population
of those eligible for transcatheter aortic valve implantation (TAVI).1
Commonly used risk scores for mortality and morbidity in coron-
ary heart surgery, like the Society of Thoracic Surgeons risk score
(STS score) and European System for Cardiac Operative Risk
Evaluation (EuroSCORE), are based on age and comorbidity.2,3
However, by omitting frailty, sensitivity of these scores to predict ad-
verse events in the oldest population is limited.4–6 Frailty, a condition
frequent in older adults, is defined as a state of impaired physiologic
reserve and decreased resistance to stressors which increase the
risk of an adverse outcome.7,8 Frailty status enhances prognostic
sensitivity for patients with multiple heart conditions including
acute coronary disease, stable angina, heart failure, 9–11 and
TAVI.12,13 A recent systematic review confirmed the relationship
between frailty and mortality in the TAVI population, with a more
than doubled risk [hazard ratio (HR) 2.35] of early (<_30 days)
death in frail patients, and a 1.63 HR of later death.14 Although
TAVI has been assessed to be cost-effective compared with med-
ical treatment,15 this is undermined by early mortality after TAVI.
As the population of older adults expands, it is important to select
patients who will benefit most from the intervention to best
justify its expense.16
Both US and European guidelines recommend the use of a Heart
Team in decision making prior to treatment for severe, symptomatic
aortic stenosis.17,18 In addition to the assessments by the interven-
tional cardiologist, cardiac surgeons and imaging specialists, the guide-
lines recommend a frailty assessment to evaluate cognition and
physical function using validated checklists.17 However, it is not
described in detail who should perform and evaluate the frailty as-
sessment and which tools to use.1,17,19 Recently, Afilalo et al.20 dem-
onstrated that the essential frailty toolset (EFT) outperformed other
frailty scores in predicting 1-year mortality in TAVI patients.
Nonetheless the authors emphasized that the EFT is primary a screen
for frailty. Once patients are identified by the EFT, further geriatric as-
sessment (GA) is recommended. This demands a more thorough
clinical evaluation. We developed a novel frailty score that provides
additional information, based on a comprehensive GA. In this study,
we show the utility of this novel GA frailty score to predict 2-year
mortality, showcasing its powerful prognostic value.
Methods
Study design
A prospective, observational cohort study with 2-year follow-up and in-
clusion of elective TAVI patients from 2011 to 2015. The study was
approved by the Regional Committee for Medical Research Ethics (REK
2010/2936-6 and 2013/1310). All participants signed an informed consent
before assessment.
Participants
Patients with severe and symptomatic aortic stenosis accepted for TAVI
were recruited from a tertiary university hospital in Western Norway
serving a population of 1.1 million. All patients were recruited the day be-
fore the procedure and were assessed by a Heart Team consisting of a
cardiac surgeon, an interventional cardiologist and an imaging specialist.
Based on the evaluation, patients were all turned down for open heart
surgery due to comorbidity and/or high EuroSCORE. The recruitment
period lasted from February 2011 to April 2015. From February 2011 to
September 2013, 65 patients >_80 years also participating in a concomi-
tant study of delirium were included.21 From October 2013 to April
2015, 82 patients >_70 years were included (Figure 1). Age was then
adjusted to 70 years as frailty was assessed to be important also in this
younger group. Exclusion criteria were declined consent or inability to
understand and/or speak Norwegian.
Severe aortic stenosis was defined as maximal Doppler velocity across
the aortic valve >_4m/s, a mean gradient >_40mmHg or an aortic valve
area <1 cm2 (indexed area <0.6 cm2/m2) and concomitant clinical symp-
toms indicating severe aortic stenosis.
Development of a novel frailty score
The GA frailty score was developed based on a comprehensive GA
which includes cognition, instrumental activity of daily living, nutrition,
physical frailty, comorbidity, and psychological health.22,23 The method
for developing this score is described by Harrell.24 In this method expert
clinicians assign severity points to each condition and sum the points in a
total score. Three geriatricians (A.W.S., A.H.R., and E.S.) and one cardi-
ologist (J.E.N.) independently ranked the clinical severity of signs within
each potentially important domain. The suggestions were sent to the first
author who developed a combined frailty score based on the different
proposals.24 All cut-off values in this combined score were based on pre-
vious studies.13,22 The researchers then agreed on the GA frailty score, a
0–9 point numeric scale with 8 validated geriatric variables (Table 1). The
score was finalized before the statistical analysis were performed.
Figure 1 Patient recruitment flowchart.


































































































Baseline data were collected by L.S.P.E. and E.S. All baseline examinations
were performed the day before the procedure. Cognition was assessed
by the Mini Mental Status Examination (MMSE).25 It has a range from 0 to
30, with higher scores indicating better cognition. Different cut-offs are
reported, and we chose a weighted score with one point for possible
cognitive impairment/mild dementia and two points for probable
dementia.13,26
Instrumental activities of daily living was measured by Nottingham
Extended Activities of Daily Living scale (NEADL),27 a 22-item question-
naire assessing mobility, kitchen, domestic, and leisure activities. Each
item has a score from 0 to 3, and the items are added to a total score
from 0 to 66, with a higher score indicating better functioning. A cut-off
<_43 suggests that the patient is dependent, and studies have shown that
this predicts complications and mortality after elective surgery in older
patients.28,29
Nutrition was assessed by the body mass index (BMI) and the weight
question of modified Study of Osteoporotic Fractures index. The cut-off
value for BMI was based on the nutritional risk screening 2002, a screen-
ing instrument for nutritional risk.30
Physical frailty was assessed by a modified version (patients self-
reported weight loss past year, not measured as in the original index)
of the Study of Osteoporotic Fractures Index (mSOF index).31 This
validated index has a maximum of three points: (i) One point if the pa-
tient has >5% weight loss the previous year (Since, we only had base-
line characteristics, the patients were given one point if answering yes
to the question ‘have you lost weight during the past year’), (ii) one
point if the patient is unable to rise from a chair without using their
arms (This was tested by L.S.P.E./E.S., not reported by the patients.),
and (iii) one point if the patient answers no to the question ‘Do you
feel full of energy?’.
Comorbidity was assessed by Charlson comorbidity index. This is a
weighted index based both on the numbers of diseases and the serious-
ness of each disease. A score of 1 is assigned for myocardial infarction,
congestive heart failure, dementia, etc., while the highest score of 6 is
given to metastatic solid tumours and AIDS. In the original paper describ-
ing the index, Charlson et al.32 recommends a high cut-off of 2 or 3 if the
mortality in the disease under study is high, and we chose a cut-off >_3.
Psychological health was assessed by the Hospital Anxiety and
Depression Scale (HADS),33 with seven questions on anxiety and seven
on depression. Each question ranges from 0 to 3. Summing up the anxiety
and depression subscales, we get total HADS, of which a cut-off >_15 was
used to identify symptoms of anxiety and/or depression.33,34
The modified essential frailty toolset
The Essential Frailty Toolset (EFT) is a brief four-item (chair rise,
cognition, haemoglobin, and serum albumin) frailty scale that predicts
morbidity and mortality after TAVI.20 Afilalo recommends applying this
scale as a screening tool.20 In this study, we aimed to compare the GA
frailty score to the EFT.
However, for the first 62 patients in our study, we only had informa-
tion on success/failure of chair rise, not on the number of seconds it took
to complete the chair rises. Therefore, when calculating the EFT for these
patients, we assigned 0 points if they completed five sit-to-stand repeti-
tions without using arms (chair rises) and 2 points if they failed to com-
plete all five chair rises. We refer to this modified methodology for the
EFT as the modified Essential Frailty Toolset (mEFT). This might give
some patients one point lower total score (i.e. the patients who used
>_15 s to perform chair rise). For three patients, wemissed serum albumin
values, and the mEFT was thus calculated for 139 patients.
Follow-up measurements
Two-year all-cause mortality has been stated as a clinically relevant out-
come for TAVI candidates and was the primary outcome of this study.1
The Valve Academic Research Consortium-2 (VARC 2) consensus docu-
ment6 recommends the use of composite endpoints after TAVI, and we
report this for the first 6months.
Power analysis
The initial power analysis was based on categorizing the patients into
three groups, a fit group, an intermediate group and a frail group, with
25% in the frail group.22,35,36 To achieve a power of 80% with a 5% level
of significance, power calculations showed that we needed a total of 140
patients. To account for dropouts, we included 5% more, a total of 147
patients. In order to make the frailty score more applicable in clinical
practice, we ultimately dichotomized it into frail and non-frail (fit and
intermediate). In addition, we analysed frailty as a continuous score,
which increases the statistical power.
Statistical analyses
We present the data as means and standard deviations (SDs), counts and
percentages, or proportions and Hazard Ratios (HRs) with 95% confi-
dence intervals (CIs), as appropriate. To assess whether the new frailty
score could predict mortality within 2 years, and also when adjusted for
other common predictors, we fitted Cox regression models with Firth’s
correction. Firth’s correction provides reduced bias when there are few
events (deaths) compared with the number of predictors. The regression
models included frailty score as a continuous predictor (unadjusted
model/trend test), or frailty score, age, gender, and logistic EuroSCORE
as predictors (adjusted model). We also fit a similar adjusted model with
frailty score as a dichotomized variable. We present time to death strati-
fied by frailty score (continuous or dichotomized ) using Kaplan–Meier
plots.
The Receiver Operating Characteristic (ROC) curve37 was examined
to find cut-off values for the dichotomized GA frailty score.We reported
the Area Under the Curve (AUC) as a summary measure.We found two
.................................................................................................
Table 1 Geriatric assessment tools used in the novel
frailty score, along with the corresponding scoring
scheme
Domain Cut-off Points
Cognition MMSE >_27 0
MMSE 20–26 1
MMSE <20 2
Instrumental activity of living NEADL <_43 1
Nutrition BMI <20.5 1
Energy level SOF index Low energy 1
Weight loss SOF indexa Weight loss 1
Limb strength SOF index Chair stand (not able) 1
Comorbidity Charlson comorbidity index >_3 1
Psychological factors HADS (total score) >_ 15 1
Total Maximum score 9
The total score is calculated by adding the different domain scores.
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; MMSE,
Mini Mental Status Examination; NEADL, Nottingham Extended Activity of Daily
Living Scale; SOF Study of Osteoporotic Fractures index.
aModified from the original SOF; see ‘Measurements’ section for details.
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cut-off values with an estimated high sensitivity and specificity, and chose
the one (>_4) emphasizing specificity over sensitivity. Confidence intervals
for the sensitivity and specificity were calculated using theWilson (score)
method.38
Some patients had missing data for a few of the questions in the HADS
and NEADL questionnaires. Where it was unambiguous on which side of
the cut-off the total score would fall on, we used the data for these
patients; otherwise, the patients were excluded. For one secondary ana-
lysis (based on the mEFT frailty scale), there were additional missing data.
For all analyses, we report the number of observations used.
Statistical analyses were performed using IBM SPSS Statistics 24 and R
version 3.5.0.39 Cox regression with Firth’s correction was performed
using R ‘coxphf’ package40 version 1.13, and the ROC and AUC calcula-




A total of 147 patients with severe and symptomatic aortic stenosis
were included. Of these, 142 patients had enough data so that the
frailty score could be computed (Figure 1). Of the 142 patients, 54%
were women, mean age was 83 years (SD 4), five patients were less
than 75 years old and three patients were 90 years or older. The old-
est patient in the study was 95 years old. More than half of the
patients lived with their spouse.
Geriatric characteristics
More than half of the patients (56%) did not have significant cognitive
disturbance, a MMSE of 27 or higher. The others (44%) had possible
cognitive impairment, but for most of them (89%) probably mild cog-
nitive impairment or mild dementia (MMSE 20–26). Most patients
(82%) had a NEADL score above 43, suggesting they were independ-
ent in activities of daily living. Few patients (13%) had low BMI (below
20.5 kg/m2); however, 52 (37%) patients had a reported weight loss
during the last year. Sixty-one (43%) of the patients had a high score
of >_3 on the Charlson comorbidity scale.
Cardiovascular characteristics
Almost all patients 127/135 (missing data on seven patients) had an
indexed aortic valve area below 0.6 cm2/m2. Logistic EuroSCORE
was below 10 in 18% and over 20 in 30% of the patients. Half of the
patients had New York Heart Association III or IV at the time of the
procedure (Table 2).
Follow-up
No patients were lost to follow-up.
Mortality and morbidity
Fifteen patients (11%) had died within 2 years, 11 of cardiovascular
causes and four of non-cardiovascular causes. There was a high de-
gree of early device success, with 141/142 (99.3%) valves in the cor-
rect position with good valve function. Early (<_30days) mortality was
seen in four patients (2.8%). Moderate to severe prosthetic valve re-
gurgitation and stroke occurred within 6 months in 12.7% and 4.8%
of the patients, respectively (Table 3).
.................................................................................................






Age, years 83.4 4.0
Women 76 (54%)
Living alone 60 (42%)
Education
Primary school 88 (62%)





MMSE >_27 80 (56%)
MMSE 20–26 55 (39%)
MMSE <20 7 (5%)
Activities of daily living
NEADL <_43 121 (82%)
Nutrition
BMI 25.0 3.9
BMI <20.5 19 (13%)
SOF index
Weight lossa 52 (37%)
Low energy 58 (41%)
Unable to chair stand 42 (30%)
Comorbidity
Charlson comorbidity index 2.53 1.3
Charlson comorbidity index >_3 61 (43%)
Psychological factors
HADS >_15 17 (12%)
Cardiovascular characteristics
Logistic EuroSCORE 17 8.7
Aortic valve area index, cm2/m2 b 0.4 0.12
Mean aortic valve gradient, mmHgc 47.6 14.4
Left ventricular ejection fraction 56.4 11
NYHA >_III 67/134 (50%)
Previous myocardial infarction 34 (24%)
CABG 31 (22%)
Permanent pacemaker 12 (9%)
Atrial fibrillation 45 (32%)
Pulmonary hypertension 45/139 (32%)
Cerebral vascular disease 16 (11%)
Comorbidity
COPD 31 (22%)
Kidney failure; creatinine >177 mmol/Ld 5 (4%)
MMSE, Mini Mental Status Examination; NEADL, Nottingham Extended Activities
of Daily Living Scale; BMI, Body Mass Index; SOF Index, Study of Osteoporotic
Fractures Index; HADS, Hospital Anxiety and Depression Scale; NYHA, New
York Heart Association Functional Classification of Heart Failure, Range From I-
IV, Most Severe Symptoms at IV; CABG, Coronary Artery Bypass Grafting;
COPD, Chronic Obstructive Pulmonary Disease.
aModified from the original SOF index; see ‘Measurements’ section for details.
bMissing data on seven patients.
cMissing data on two patients.
dAs reported in the PARTNER study; creatinine >2mg/dL (177 mmol/L).1



































The distribution of frailty scores and the corresponding 2-year mor-
tality is shown in Table 5. Based on the dichotomized GA frailty score,
34 patients (24%) were characterized as frail (score >_4).
The Cox analyses showed that the continuous GA frailty score
predicted mortality within 2 years, with an estimated HR of 1.79 (95%
CI: 1.34–2.36, P<0.001), i.e. an estimated 79% increase in hazard for a
unit increase in GA frailty score. This predictive power also remained
(HR = 1.75, 95% CI: 1.28–2.42, P<0.001) when adjusting for age, gen-
der, and logistic EuroSCORE (Table 4). A test of the proportional haz-
ard assumption did not find any problems with the model (P=0.77).
The corresponding results for the dichotomous GA frailty score
were HR = 5.35 (95% CI: 1.99–15.3, P=0.001) (unadjusted) and HR
= 4.91 (95% CI: 1.79–14.2, P=0.002) (adjusted).
The ROC curve (Figure 2) illustrates that a frailty score cut-off
at >_4 predicts 2 year mortality with a specificity of 80% (95% CI:
73–86%) and a sensitivity of 60% (95% CI: 36–80%). The AUC was
0.81 (95% CI: 0.71–0.90).
None of the patients with a frailty score of 0 or 1 were dead after
2 years, and none of the patients had a frailty score of 8 or 9. In gen-
eral, the higher the frailty score, the higher the risk of dying within 2
years (Table 5).
When adjusting for mEFT along with age, gender, and logistic
EuroSCORE, the continuous GA frailty score were no longer a
statistically significant predictor (HR = 1.36, 95% CI: 0.87–2.21,
P=0.18, n=139), and neither were any of the other variables
(including mEFT).
Discussion
In this prospective observational study, we found that a novel GA
frailty score could predict 2-year all-cause mortality in TAVI
....................................................................................................................................................................................................................
Table 3 Composite endpoints according to Valve Academic Research Consortium-2 consensus documenta criteria
Total (N 5 142) Percent
Device success
Absence of immediate procedural mortalityb 142 100
Correct positioning 141 99.3
Intended performance of the prosthetic heart valvec 141 99.3
No moderate or severe prosthetic valve regurgitationd 135 95.1
Early safety(at 30 days)
All-cause mortality 4 2.8
All stroke(disabling or non-disabling) in hospitale 4 2.8
Life-threatening or disabling bleeding 8 5.6
Acute kidney injury Stage 2 or 3f 3 2.1
Coronary artery obstruction requiring intervention 1 0.7
Major vascular complication 6 4.2
Valve-related dysfunction requiring intervention 1 0.7
Clinical efficacy(30 days–6 months)
All-cause mortality 6 4.2
All stroke(disabling or non-disabling) 3 2.1
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure 15 10.6
NYHA class III or IVg 9/136 6.6
Time-related valve safety
Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient >_20 mmHg) and/ or moderate or severe
prosthetic valve regurgitationh
18/141 12.7
Requiring repeat procedure (TAVI or SAVR) 1 0.7
Prosthetic valve endocarditis 1 0.7
Trombo-embolic events (e.g. stroke) 7 4.8
VARC bleeding (life threatening/disabling bleeding or major bleeding) and unless clearly unrelated
to valve therapy (e.g. trauma)
28 19.7
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; NYHA New York Heart Association.
aThe Valve Academic Research Consortium (VARC)-2 consensus document (see references).
bImmediate or consequent death <_72 h post-procedure.
cNo prosthesis patient mismatch and mean aortic valve gradient <20mmHg or peak velocity <3 m/s.
dAfter TAVI procedure at index hospitalization.
eAssessment of stroke at index. All strokes verified by imaging (CT or MRI).
fEvaluation of acute kidney injury is based on serum creatinine, we miss data on urine output.
gNew York Heart Association (NYHA), missing data on six patients.
hFollow-up at 6months, missing data on one patient.






























































patients declined for open heart surgery by a Heart Team. After 2
years, there were no deaths in the cohort with very low (0 or 1)
frailty score.
Standard risk scores like EuroSCORE and STS score are insuffi-
cient for predicting adverse events in the older adult,11,13,42 and a
frailty assessment adds information which increases predictability.
There is an ongoing discussion regarding the definition of frailty and
whether to include cognition, psychological factors, and comorbid-
ity.43 The GA frailty score was developed to provide information for
a better decision making prior to TAVI. This study adds to previous
work highlighting the need for a more thorough evaluation of the in-
dividual patient based on a comprehensive GA. This can provide sig-
nificant decision-making support for the interventional cardiologist or
surgeon. The purpose of the score is not to screen all TAVI candi-
dates, as this will be too time-consuming. Rather it should be used in
patients in whom a simpler screening44 has revealed potential
obstacles for TAVI. In this setting, an assessment solely on physical
frailty would not be sufficient, in part due to decline in physical
performance related to severe aortic stenosis. An approach with an
initial basic screening for frailty and a selective thorough assessment
by a geriatrician has been advocated.44,45
Patients categorized as frail might still be eligible for TAVI. All
patients should be involved in a shared decision process regarding
their treatment, but for patients where there is doubt whether the
procedure is beneficial, it is especially important. Previous studies
have underlined the importance of exploring patients’ perspec-
tives.46,47 Asking the question ‘What do you hope to accomplish by
having your valve repaired?’ might capture what is most important to
patients.48 The decision to offer TAVI should in the end be made by
the interventional cardiologist or cardiac surgeon performing TAVI,
based on an analysis of benefit vs. risk, taking into account symptoms,
comorbidity, patient perspective, procedural risk, and frailty.We sug-
gest the geriatrician to be an important collaborator in this analysis. If
TAVI is offered despite frailty, the treatment team should be pre-
pared for a higher risk of complications, including delirium.21 Ideally,
detecting frailty should lead to additional pre-, per-, and post-opera-
tive support.11 The GA frailty score provides delineation of specific
aspects of frailty that can be addressed (e.g. nutritional supply if
undernourished, treatment for depression).49,50 We do not have
enough evidence to recommend specific exercise before TAVI in
order to improve frailty status.
This study confirms the clinical relevance of frailty assessment
prior to TAVI.12,13,17 The GA frailty score evaluating cognition, in-
dependence in daily life, nutrition, physical frailty, comorbidity,
and psychological health, give a thorough and comprehensive as-
sessment of the patient. A high GA frailty score >_4 indicates a
reduced 2-year survival (Figure 3). However, we do not advocate
a strict cut-off where TAVI is not offered. Knowledge of the (0–9
based) GA frailty score should lead to a careful final evaluation by
the TAVI team, and should involve weighting frailty, technical
challenges, exploring patient preferences, and symptom burden
before offering TAVI. The geriatrician can contribute to the heart
team as a frailty expert.
.................................................................................................
Table 5 Distribution of geriatric assessment frailty









0 15 11 11 0 0
1 26 18 29 0 0
2 39 27 56 2 5
3 28 20 76 4 14
4 20 14 90 4 20
5 10 7 97 3 30
6 2 1 99 2 100
7 2 1 100 0 0
8 0 0 100 — —
9 0 0 100 — —
Cum., cumulative; Prop., proportion.
aDeaths within 2 years after TAVI.
Figure 2 Receiver operator characteristics curve for geriatric as-
sessment frailty score (0–9) and 2 year mortality (n=142). The area
under the curve is 0.81 (95% confidence interval: 0.71–0.90).
................................... ...................................
.................................................................................................
Table 4 Cox regression (with Firth’s correction)
(n5 142)
Unadjusted Adjusted
HR 95% CI P-value HR 95% CI P-value
Age, years 1.16 1.00–1.37 0.04 1.16 1.01–1.37 0.04
Male gender 1.01 0.37–2.71 0.99 2.14 0.68–6.93 0.19
Logistic
EuroSCORE
1.06 1.01–1.11 0.02 1.04 0.99–1.08 0.13
GA frailty score 1.79 1.34–2.36 0.001 1.75 1.28–2.42 <0.001
CI, confidence interval; HR, hazard ratio.
Hazard ratio estimates (with 95% confidence intervals) for death within 2 years
of transcatheter aortic valve implantation. The hazard ratios show the increase in
hazard for a unit increase in age (years), logistic EuroSCORE and/or GA frailty
score, and for males compared with females.





























































































Strengths of the study
This is a prospective study, with potentially fewer sources of bias
and higher quality of data than a retrospective study would have.
In Norway, deaths of all patients are automatically registered
in the patients’ electronic journal. Our primary outcome is there-
fore complete. We also have high completeness in the rest of our
data, and importantly, no patients are lost to follow-up for the
primary endpoint. The variables included in the GA frailty score
were determined before the statistical analysis, eliminating the
risks associated with a purely data-driven analysis. Finally, our
risk score was reliable in patients already excluded from surgery
due to comorbidity.
Limitations of the study
Survival with benefit after 2 years is advocated as a relevant clinical
endpoint, and it would have strengthened the study if we also
assessed quality of life in the patient 2 years after the procedure.1
However, there are limitations to soft endpoints, and in order to sim-
plify the interpretation of the frailty score, we chose to focus mainly
on prediction of mortality. Some items were self-reported and not
performance based, introducing some subjectivity to the index; how-
ever, previous studies have showed for all the selected self-report
items to be markers of frailty.7,31 This is a single-centre study, and the
results might not be transferable to any other centre, although they
are probably comparable to other European centres of the same
size. The study population changed during the study. Initially, inclusion
consisted of patients >_80 years, but was later expanded to include all
patients >_70 years. This was partly due to a shift in the general TAVI
population, but also a growing awareness that frailty is a complex
phenomenon where age is only one contributing factor.7 The partial
lack of data used in calculating the EFT score reduces the precision of
the score somewhat. And finally, the small sample size (especially the
few number of deaths) is a limitation, particularly for calculating the
sensitivity of the dichotomized frailty score in predicting 2-year mor-
tality. Before recommending the GA frailty scale, it needs to be vali-
dated in an independent population.
Conclusions
In patients declined for open heart surgery, an 8-element frailty score
based upon GA can identify patients less likely to benefit from TAVI.
Patients with a frailty score >_4 had significantly higher 2-year mortal-
ity. We believe the novel GA frailty score has clinical relevance and
may be a useful tool for heart teams in decision making for TAVI.
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Abstract
Aims The objective of this study was to examine baseline frailty status (including cognitive deficits) and important clinical 
outcomes, to inform shared decision-making in older adults receiving transcatheter aortic valve implantation (TAVI).
Methods and results We conducted a prospective, observational study of 82 TAVI patients, recruited 2013 to 2015, with 
2-year follow-up. Mean age was 83 years (standard deviation (SD) 4.7). Eighteen percent of the patients were frail, as assessed 
with an 8-item frailty scale. Fifteen patients (18%) had a Mini-Mental Status Examination (MMSE) score below 24 points 
at baseline, indicating cognitive impairment or dementia and five patients had an MMSE below 20 points. Mean New York 
Heart Association (NYHA) class at baseline and 6 months was 2.5 (SD 0.6) and 1.4 (SD 0.6), (p < 0.001). There was no 
change in mean Nottingham Extended Activities of Daily Living (NEADL) scale between baseline and 6 months, 54.2 (SD 
11.5) and 54.5 (SD 10.3) points, respectively, mean difference 0.3 (p = 0.7). At 2 years, six patients (7%) had died, four (5%, 
n = 79) lived in a nursing home, four (5%) suffered from disabling stroke, and six (7%) contracted infective endocarditis.
Conclusions TAVI patients had improvement in symptoms and maintenance of activity of daily living at 6 months. They had 
low mortality and most patients lived in their own home 2 years after TAVI. Complications like death, stroke, and endocar-
ditis occurred. Some patients had cognitive impairment before the procedure which might influence decision-making. Our 
findings may be used to develop pre-TAVI decision aids.
Keywords Aortic stenosis · TAVI · Activity of daily living · Shared decision making · Older adults
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Introduction
Transcatheter aortic valve implantation (TAVI) is an estab-
lished treatment for severe and symptomatic aortic stenosis 
in patients not eligible for open heart surgery, and it improves 
symptoms and increase life expectancy [1, 2]. While indi-
cation for TAVI has expanded to also include younger and 
lower risk groups, the majority of TAVI patients are older 
and have significant comorbidity and frailty that contraindi-
cated surgery. The Valve Academic Research Consortium-2 
(VARC 2) consensus document recommends evaluation of 
independence in activity of daily living before the procedure 
as risk stratification [3]. However, few studies have focused 
on independence in activity of daily living as an outcome 
measure [4, 5].
Among older adults who are seriously ill, death might not 
be feared as the worse outcome. For many, reduced quality 
of life and functional or cognitive impairment [6, 7], are 
relatively greater concerns. Dementia is highly prevalent in 
older adults [8] and is the leading cause of dependency in 
older age [9]. Shared decision-making is the favoured model 
for health care decisions, enhancing treatment choices to 
reflect patients’ values and preferences [10]. However, the 
context of cognitive impairment or dementia makes it more 
difficult for TAVI candidates to participate in the decision-
making process [11].
Thus, the aim of this study was to examine baseline frailty 
status including cognition and outcomes important to deci-
sion-making prior to TAVI.
Methods
Study design
This is a single-centre prospective, observational cohort 
study of 82 elective TAVI patients, with 2-year follow-up. 
Ninety-four patients were eligible for inclusion, five refused 
to participate and seven were not included due to logisti-
cal reasons. The patients were recruited consecutively from 
2013 to 2015.
Participants
Patients ≥ 70 years with symptomatic and severe aortic ste-
nosis accepted for TAVI at Haukeland University Hospital in 
Western Norway were included. The hospital has a tertiary 
function for TAVI and serves a population of 1.1 million 
inhabitants. Severe aortic stenosis was defined by echocar-
diography according to the European Society of cardiology 
(ESC) guidelines [1]. Before accepting patients for TAVI, 
a heart team including interventional cardiologists, cardiac 
surgeons and imaging specialists, had declined them for sur-
gical aortic valve replacement due to high risk. At the time 
of the study, there was no screening for frailty preceding the 
intervention, and the frailty score of the study patients was 
not known to the treatment team. The number of patients 
selected for conservative treatment is not known but sus-
pected to be small. Nursing home patients and patients with 
severe dementia are rarely referred for valve intervention in 
Norway. Exclusion criteria were inability to understand or 
speak Norwegian.
Procedural characteristics
TAVI was delivered by different routes, seventy five (92%) 
trans-femoral, five trans-subclavian and two with direct aor-
tic access. Two different valves were used, the Medtronic 
Core Valve in 52 (63%) and Boston Scientific LOTUS Valve 
in 30 (37%) patients.
Measurements
Baseline
Mini-Mental Status Examination (MMSE) assesses cogni-
tion as a scale that ranges from 0 to 30, with higher scores 
indicating better cognition [12]. The cut-off for normal 
cognitive function is usually set at 24, with a sensitivity 
of 0.85 and a specificity of 0.90 for identifying anyone 
with dementia [13].
The research team developed an 8-item frailty scale 
[14]. The total score is calculated by adding different 
domain scores: cognition (MMSE ≥ 27 = 0 points, MMSE 
20–26 = 1 point, MMSE ≤ 19 = 2 points), instrumental 
activity of daily living (NEADL ≤ 43 = 1 point), nutrition 
(BMI < 20.5 = 1 point), modified SOF (low energy = 1 
point, weight loss (reported, not measured weight loss; 
therefore, modified) = 1 point, chair stand, not able = 1 
point) [15], Charlson Comorbidity Index (≥ 3 = 1 point) 
[16], and psychological factors (HADS ≥ 15 = 1 point) 
[17]. The score range from 0 to 9, were 9 represents 
the frailest patients. Patients were classified frail if they 
scored ≥ 4 points. This cut-off had a specificity of 80% and 
sensitivity of 60% at predicting 2-year mortality for this 
population. In a receiver operating curve, the area under 
the curve was 0.81 (95% confidence interval 0.71–0.90) 
[14].
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Baseline and 6 months:
Nottingham Extended Activity of Daily living scale 
(NEADL) is a scale originally developed to assess activi-
ties of daily living (ADL) for stroke patients discharged to 
home, yet frequently used in non-stroke populations [18, 
19]. The scale measures extended activities of daily living 
using a 22-item questionnaire, evaluating four different 
sections: mobility, kitchen, domestic and leisure. Patients 
are asked whether they perform the different activities, and 
the response categories are 0 = not at all, 1 = with help, 
2 = on my own with difficulty, 3 = on my own. The dif-
ferent scores sums into a total score of 0 to 66 points, 
with higher scores indicating greater independence. A 
score ≤ 43 indicates dependence [19]. One study of stroke 
patients reported a valid and reliable change if the NEADL 
improved or deteriorated by 4.9 points or more, and clini-
cally important if the mean change score was in the range 
from 2.4 to 6.1 points after treatment [20].
The New York Heart Association (NYHA) classification 
describes patients’ symptoms of heart failure [21] and has 
been applied to TAVI patients [3]. NYHA class I repre-
sents no symptoms of heart failure and no limitation of 
physical activity, while NYHA class IV represents symp-
toms of heart failure at rest. Despite limitations it’s widely 
used both in research and clinical practice.
Follow‑up measurements
Baseline NEADL and NYHA were assessed and then 
repeated at 6 months. Due to some patients living far from 
the hospital, we performed telephone interviews at 6 months, 
and MMSE and frailty testing were, therefore, not con-
ducted. For the first 2 years, we recorded composite end-
points as recommended by the Valve Academic Research 
Consortium-2 (VARC-2) consensus document. We collected 
data of admission to long-term nursing homes for the first 
2 years.
Statistical analyses
We present the data as means and standard deviations (SD), 
counts and percentages. Changes from baseline to 6 months 
are analysed using paired t-tests. There were little missing 
data so we have used complete case analysis and report the 
number of observations each analysis is based on. Statisti-
cal analysis was carried out in IBM SPSS Statistic 24 and R 





We examined 82 patients with severe and symptomatic aor-
tic stenosis, 39 (48%) women. Mean age was 83 years (SD 
4.7), two patients were over 90 years, the oldest 95 years old, 
and there were six patients under 75 years. Most patients 
(62%) lived with their spouse. A majority (55%) had only 
primary school, while 20% had a university degree.
Geriatric characteristics
Fifteen patients (18%) had an MMSE score < 24, suggest-
ing they were cognitively impaired. One fifth of the patients 
had a low NEADL score (≤ 43), implying dependence in at 
least one instrumental activity of daily living. As expected, 
NEADL and MMSE was correlated (Spearman’s rho = 0.47, 
p < 0.001). Eleven patients had a low BMI, however, 27 
(33%) reported weight loss last year. Charlson comorbid-
ity index was ≥ 3 in 36 (44%) of the patients, demonstrat-
ing a high burden of comorbidity. Six (7%) patients had a 
score ≥ 15 on the Hospital Anxiety and Depression Scale; 
i.e., few patients had severe anxiety or depression. For 80 
patients, baseline 8-item frailty scale was calculated, and 14 
patients (18%) were defined as frail.
Cardiovascular characteristics
Logistic EuroSCORE [23] was below 10 (predicting low 
surgical risk) in 20 (24%) and over 20 (high surgical risk) in 
19 (23%) of the patients. Almost half (48%) of the patients 
had NYHA ≥ 3 at baseline, indicating a significant bur-
den of symptoms. Few patients (11%) had a pacemaker 
before TAVI, and 26 (32%) had atrial fibrillation at baseline 
(Table 1).
Follow‑up
One patients was lost to follow-up at the telephone inter-
view and three had died. For three patients, information was 
missing on whether they lived at home or in nursing home 
at 2-year follow-up. VARC 2 composite endpoint is pre-
sented in Table 2, and endocarditis is separately presented 
in Table 3 with complementary data.
Mortality and morbidity
Two patients (2%) died early (< 30 days), and one had a 
disabling stroke. At 1 year, four patients (5%) had died and 
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4 (5%) had a disabling stroke. After 2 years, 6 (7%) patients 
had died, five of cardiovascular and one of non-cardiovascu-
lar cause. Four patients lived in nursing homes. There were 
no new disabling stroke from one to 2 years. Six patients 
(7%) had endocarditis during the first 2 years. Thirty-two 
patients (39%) got a new pacemaker perioperative (during 
the hospital stay).
Patient‑reported outcome measures at 6 months
NEADL
The NEADL score was available in 78 patients at 6 months. 
All patients were reached in person except for one, where the 
spouse provided information. For one patient, only NEADL 
at 6 months was available. There was no change in mean 
NEADL (n = 77) at baseline and 6 months with 54.2 (SD 
11.5) and 54.5 (SD 10.3), respectively, mean difference 
0.3 (p = 0.7). Even so, 13 patients (17%) improved 5 points 
or more at the NEADL from baseline to 6 months, and 14 
patients (18%) deteriorated 5 points or more. We did not 
find an association between frailty status and deterioration in 
NEADL score. For example, the proportion of patients who 
deteriorated in NEADL score was similar in the frail and 
the non-frail group (42% and 55%, respectively, p = 0.53, 
Fisher’s exact test).
NYHA class
After 6 months, the majority was in NYHA I (68%), about 
a quarter were in NYHA II (27%) and a few in NYHA III 
(5%). No patients were in NYHA IV. Mean NYHA (n = 78) 
at baseline and 6 months was 2.5 (SD 0.6) and 1.4 (SD 0.6), 
respectively, a significant improvement (p < 0.001). Four 
patients had missing NYHA class at 6 months (three dead, 
one lost to follow-up) (Fig. 1).
Table 1  Patient baseline characteristics (n = 82)
The total score is calculated by adding the different domain scores
MMSE mini-mental status examination, NEADL Nottingham 
extended activities of daily living scale, BMI body mass index, SOF 
study of osteoporotic fractures, HADS hospital anxiety and depres-
sion scale
Mean or count SD or (percent)
Characteristics
 Age, years 83 4.7
 Women 39 (48)
 Living alone 29 (35)
 Education
  Primary School 45 (55)





  MMSE ≥24 67 (82)
  MMSE 20–23 10 (12)
  MMSE <20 5 (6)
 Activities of daily living
  NEADL ≤43 15/80 (19)
 Nutrition
  BMI 24.8 3.6
  BMI <20.5 11 (13)
 mSOF
  Weight  lossa 27 (33)
  Low energy 32 (39)
  Unable to chair stand 10 (12)
 Comorbidity
  Charlson Comorbidity Index 2.6 1.4
  Charlson Comorbidity Index ≥3 36 (44)
 Psychological factors
  HADS ≥15 6/81 (7)
 Frailtyb 14/80 (18)
Cardiovascular characteristics
 Logistic EuroSCORE 15 7.9
 Aortic Valve Area Index,  cm2/m2 0.4 0.12
 Mean Aortic Valve gradient, 
mmHg
50 15
 Left ventricular ejection fraction 57 12
 NYHA ≥III 39 (48)
 Previous myocardial infarction 15 (18)
 CABG 15 (18)
 Permanent pacemaker 9 (11)
 Atrial fibrillation 26 (32)
 Pulmonary hypertension 27 (33)
 Cerebral Vascular Disease 12 (15)
Comorbidity
 COPD 19 (23)
 Kidney failure; creatinine >177 
µmol/Lc
4 (5)
a Modified from the original SOF, with patient-reported weight loss 
past year, not measured as in the original index (mSOF modified 
SOF)
b 8-item geriatric assessment frailty scale. Missing information to 
calculate the scale in two patients, NYHA, New York Heart Asso-
ciation functional classification of heart failure, range from I to IV, 
most severe symptoms at IV. CABG coronary artery bypass grafting, 
COPD chronic obstructive pulmonary disease
c As reported in the PARTNER study [2]; Creatinine > 2 mg/dl (177 
µmol/L)
Table 1  (continued)
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Discussion
This prospective observational study of 82 patients docu-
ments symptom improvement and maintenance of activities 
of daily living 6 months after TAVI. They had low mortal-
ity and most patients lived in their own home 2 years after 
TAVI. At baseline, 18% had an MMSE score, indicating 
cognitive impairment or dementia. We found a higher fre-
quency of endocarditis than expected. According to the basic 
principles of shared decisions-making, balanced information 
regarding risks and benefits, and exploring patients’ values 
and goals are important. Physicians should be aware that 
patients’ cognitive impairment or dementia might affect the 
ability to participate in the decision-making process and give 
an informed consent.
Mortality at one (5%) and 2 years (7%) after TAVI was 
low in this cohort, where mean age is over 80 years and there 
is a substantial burden of comorbidity and frailty. We found 
a substantial improvement in NYHA class from baseline 
to 6 months. Based on the improvement of symptoms we 
expected to find an improvement in NEADL. However, we 
found no change in mean NEADL. There was a variation on 
an individual level. Some patients improved their independ-
ence and others deteriorated, although for most patients, the 
Table 2  Composite endpoints according to VARC  2a criteria
SAVR Surgical aortic valve replacement, TAVI transcatheter aortic valve implantation, NYHA New York Heart Association
a The Valve Academic Research Consortium (VARC)-2 consensus document (see references)
b Immediate or consequent death ≤ 72 h post-procedure
c No prosthesis-patient mismatch. Mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/s
d After TAVI procedure at index hospitalization
e Assessment of stroke at index. All strokes verified by CT/MRI
f Evaluation of acute kidney injury is based on serum creatinine, we miss data on urine output
g NYHA at 6 months
h Four patients had new paravalvular leak or vegetation on the aortic valve
Total (n = 82) Percent
Device success
Absence of immediate procedural  mortalityb 82 100
Correct positioning 81 99
Intended performance of the prosthetic heart  valvec 81 99
No moderate or severe prosthetic valve  regurgitationd 78 95
Early safety (at 30 days)
All-cause mortality 2 2
All stroke(disabling or non-disabling) in  hospitale 1 1
Life-threatening or disabling bleeding 4 5
Acute kidney injury-stage 2 or  3f 2 2
Coronary artery obstruction requiring intervention 1 1
Major vascular complication 5 6
Valve-related dysfunction requiring intervention 1 1
Clinical efficacy (30 days–2 years)
All-cause mortality 4 5
All stroke(disabling or non-disabling) 5 6
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure 13 16
NYHA class III or  IVg 4 5
Time-related valve safety
Structural valve deterioration
 Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg) and/ or moderate or severe prosthetic 
valve  regurgitationh
15/81 19
 Requiring repeat procedure (TAVI or SAVR) 1 1
Prosthetic valve  endocarditisf 6 7
Trombo-embolic events (eg stroke) 6 7
VARC bleeding (life threatening/disabling bleeding or major bleeding), unless clearly unrelated to valve 
therapy (e.g. trauma)
14 17
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change in NEADL was minor. Other factors, like frailty and 
dementia, probably have more impact on the level of inde-
pendence than the aortic stenosis per se [4], and 6 months 
follow-up is probably too short to establish deterioration due 
to other causes. There was no difference between the frail 
and robust patients regarding change in NEADL from base-
line to 6 months.
At baseline, 15 patients had an MMSE below 24, indi-
cating possible cognitive impairment or dementia [13]. 
Five patients had an MMSE less than 20, which increases 
the probability of incapacity, and likely reduces their 
power of judgement during the decision-making processes 
before TAVI [11]. Several studies have suggested that a 
low MMSE score at baseline predicts poor outcomes after 
TAVI [4, 24]. However, there are also studies demonstrat-
ing cognitive improvement after TAVI when impairment 
is caused by the aortic stenosis itself [25]. For patients 
with established dementia, surviving to end stage dementia 
might not be what the patient would choose autonomously. 
These are difficult issues to discuss with patients with 
dementia and their families, both due to patients’ anosog-
nosia (a physiological damage to the brain, where patients 
have no awareness of their disease) [26], and also health 
care professionals’ fear of patients losing hope when 
focusing on the deterioration and increased dependence 
expected after a diagnosis of dementia [27]. It is impor-
tant to point out that an MMSE < 24 is not diagnostic of 
dementia, and sensitivity and specificity for MMSE cut-
offs in a TAVI population, might be different than in the 
general population. Suspicion of dementia should, there-
fore, lead to further investigations.
Table 3  Infective endocarditis first 2 years after TAVI
TTE transthoracic echocardiography, TEE trans-oesophageal echocardiography, PVL para valvular leak, PM pacemaker, CRT-P/D coronary 
resynchronisation therapy with cardiac defibrillator (D) or pacemaker (P)
a y years, M male, F female
b All meet criteria for definite infective endocarditis (IE) except the last patient who has a possible IE. All patients had trans-femoral access for 
TAVI
c Died five months after diagnosed with IE
d Died one month after diagnosed with IE








Dukes  criteriab Outcome two 
year
TTE and TEE Pacemaker device
Lotus 27 mm 86 y, F 49 Stafylococcus 
aureus
1 Major + 3 
minor
Dead c No vegetation or 
PVL
PM, 1 day after 
TAVI
Core valve 31 
mm
77 y, M 190 Streptococcus 
salvarius
2 Major + 2 
minor
Alive Aortic valve 
vegetation
CRT-D , 3 months 
before TAVI
Core valve 31 
mm
80 y, M 380 Enterococcus 
faecalis
1 Major + 3 
minor
Alive New aortic PVL CRT-P, 2 months 
after TAVI
Core valve 29 
mm
79 y, M 407 Streptococcus 
sanguinis
1 Major + 3 
minor
Alive New aortic PVL No
Core valve 31 
mm
77 y, M 448 Stafylococcus 
aureus
2 Major + 4 
minor
Dead d Aortic valve 
vegetation
CRT-P, 1 year 
before TAVI
Core valve 31 
mm
80 y, M 528 Streptococcus 
oralis
1 Major + 1 
minor
Alive No vegetation or 
PVL
PM, 1 day after 
TAVI
Fig. 1  Individual changes in NYHA class from baseline (n = 82) to 6 
months (n = 78). The height of each bar is proportional to the number 
of patients with the corresponding NYHA class, and the width of the 
ends of each flow line is proportional to the number of patients with 
the given pattern of change of NYHA class
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We found a higher frequency of infective endocarditis 
(IE) than expected. In a recent meta-analysis with a mean 
follow-up at 3.4 years, the overall incidence of IE in TAVI 
was 2.0% [28]. In the present study, five of six patients with 
IE had a pacemaker or an ICD, which might be associated 
with an increased risk of IE [29]. Several single-centre stud-
ies finding higher incidences suggests that IE is underre-
ported in large studies and registries [30, 31]. Diagnosing 
endocarditis is challenging, and the presentation might be 
uncharacteristic since the patients are old with comorbidities 
[28]. As endocarditis can occur later on, longer follow-up 
than 1 year seems important. Antibiotic prophylaxis during 
the TAVI procedure were administered to all patients. Gen-
eral practitioners were informed routinely on discharge about 
the risk of endocarditis and indications for prophylaxis.
Prior to TAVI, patients need to be informed of expected 
NYHA class improvement, survival benefit and maintenance 
of activities of daily living. Rare and severe complications, 
like death, stroke and infectious endocarditis, should also 
be part of the pre- TAVI discussion with the patient. Old 
patients with substantial comorbidity need to be informed 
that TAVI will not solve all their health problems. After 
the study period, written information about the procedure 
and risks and benefits was developed and administered to 
patients as part of the decision-making process. Our findings 
may be used when developing and improving decision aids 
for this treatment in older adults.
Strengths of the study
All hospitals in Western Norway use the same electronic 
medical records and VARC-2 endpoints are complete with 
no patients lost to follow-up. All deaths are automatically 
registered in the patients’ electronic journal. The same 
investigator (ES) performed the assessment at baseline and 
6 months, increasing reliability.
Limitations of the study
This is a single centre study performed in the early era of 
TAVI and some of the results might not be transferable due 
to improvement of equipment, better patient selection and 
training of the interventional cardiologists performing the 
procedure. Most patients were independent before TAVI, and 
minor (nevertheless important to patients) improvements 
might not be revealed by the NEADL questionnaire. Due to 
the small sample size, it was not possible to analyse whether 
specific subgroups improved or deteriorated in NEADL. We 
performed only telephone interviews at 6 months, prevent-
ing us from assessing MMSE and frailty at follow-up. We 
assume that living in their own home 2 years after TAVI 
reflects independence of activities of daily living, however, 
we cannot exclude that some patients living at home were 
in need of extended care.
Conclusion
TAVI patients had symptom improvement and maintenance 
of activity of daily living at 6 months. They had low mortal-
ity, and most patients lived in their own home 2 years after 
TAVI. Severe complications, like death, stroke and endocar-
ditis, occurred. Balanced information regarding these risks 
and benefits is needed to ensure informed consent prior to 
the procedure, and our findings may be used to develop 
and improve decision aids assisting this process. Clinicians 
should be aware that some patients have cognitive impair-
ment before TAVI that might affect their power of judgement 
and decision-making.
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Interview guide, TAVI decision-making process 
The original questions were in Norwegian. 
 
Background/Motivation 
1. Could you tell me, please, why you wanted this procedure? What were your 
expectations? 
   
The decision process 
2. How did you find the information about the procedure? 
3. Would you like to elaborate on what was most difficult in the decision-making? 
4. What was the most crucial factor in deciding to undergo TAVI? 
5. What did you think of the risk of complications? How much detail would you prefer 
in the information about risk before this intervention? 
6. What did you think of the risk of death associated with the procedure? 
7. How did you involve your family/relatives in the decision-making? 
8. What hope for the future mattered the most to you in the process? 
 
Closure 
9. Do you have any thoughts on how doctors and other health care professionals could 
support you better in the decision to undergo TAVI? 
10. Could you tell me a bit about how you typically face challenges/hard times in life? 
11. Finally, are there any aspects of the decision-making process that we have not 
addressed yet? And if so, would you like to add a comment on them? 
 
The interview guide was revised after two interviews, the questions marked in yellow 
being added. No questions were removed.   
Developing the frailty score: 
Frailty score Suggestion 1 Suggestion 2 Suggestion 3 Suggestion 4 Fusion 
Cognition 1 point if MMSE 
is under 24,  
2 points if 
MMSE is under 
20 
MMSE MMSE, cut- 
off < 24 
MMSE >=27/<27 
= 0/1 point 
MMSE > =27=0 
points 
MMSE 20-26 =1 
point 





e in activities 
of daily living 
NEADL NEADL  NEADL, either 
walk around 
outside, climb 
stairs) 0 point if 
you manage 
alone, 1 point for 
every other 
answer (alone 
with help etc.) or 
the whole NEADL 
dichotomized 
(but it measures 







<= 43 = 1 point  
Nutrition BMI <20 
1 point 
 BMI <20,5 
(as in NRS 
2002) 
Weight loss 
according to Fried 
 
BMI <20,5 (as in 





SOF weight loss: 
1 point 
Low energy: 1 
point 
Chair stand (not 
able) 1 point 
SOF  SOF Chair stand test: 
Yes/no= 0/1 point 
Full of energy 
question: 
Yes/no=0/1 point 
SOF weight loss: 1 
point 
Low energy: 1 
point 
Chair stand (not 
able) 1 point 
Comorbidity Charlson >3 , 1 
point 

























Page 43, Participants. The two patients recruited but not interviewed have not been 
accounted for. The correct statement is: 12 patients were recruited, one withdrew and 
one was unable to attend the interview due to hospital admission. Ten interviews were 
conducted.  
Page 43, Participants. It should be phrased: participants are listed in table 1. Not were 
list. 
Page 47, find a lower age specific incidence, not incidents. 
Paper 2 
Table 2. Most patients (82%) were independent in instrumental ADL and the number 
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